Aspects of chemotherapy and photon and proton radiotherapy in patients with gastric cancer by Gubanski, Michael
From the Department of Oncology and Pathology 
Karolinska Institutet, Stockholm, Sweden 
ASPECTS OF CHEMOTHERAPY AND 
PHOTON AND PROTON RADIOTHERAPY 





 All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Printed by Eprint AB 2015 
© Michael Gubanski, 2015 
ISBN 978-91-7549-801-0 
Aspects of Chemotherapy and Photon and Proton 
Radiotherapy in Patients with Gastric Cancer 
 




Docent Pehr Lind 
Karolinska Institutet 
Department of Oncology and Pathology 
 
Co-supervisor(s): 
Professor Bengt Glimelius 
Uppsala Universitet 
Department of Radiology, Oncology and  
Radiation Sciences  
 
Docent Nils Albiin 
Karolinska Institutet 




Professor Michael Bergqvist 
Umeå Universitet 
Department of Radiation Sciences 
 
Examination Board: 
Docent Thomas Björk-Eriksson 
Göteborgs Universitet 
Department of Clinical Sciences 
Division of Oncology 
 
Professor Mikael Karlsson 
Umeå Universitet 
Department of Radiation Sciences 
 
Docent Jan Johansson 
Lunds Universitet 



































Gastric cancer remains a major health problem worldwide. The addition of chemotherapy 
alone or in combination with radiotherapy to surgery in local gastric cancer improves 
outcome. In more advanced stages, the optimal palliative chemotherapy remains unknown, as 
well as the effect of different regimens on the patients’ quality of life. The aim of this thesis 
was to explore a new concept in chemotherapy, i.e. the sequential approach, and a new 
modality in radiotherapy, i.e. proton therapy, in the treatment of patients with gastric cancer. 
Quality of life (QoL) in patients treated with chemotherapy, and target delineation in 
radiotherapy of gastric cancer, were also studied. 
In Paper I, we evaluated the efficacy of sequential chemotherapy in patients with locally 
advanced and/or metastatic gastric cancer, with alternating irinotecan and docetaxel in 
combination with infusion 5-Fu. Eighty-one patients were randomized. No differences 
favoring either arm were found with respect to response rate, overall survival (OS), or 
toxicity. The median OS of 11 months indicated that the sequential approach was effective 
and similar to triple combinations, with potentially less toxicity. In Paper II, we evaluated the 
effect of sequential chemotherapy on the QoL in the same cohort. It was measured before, 
during, and after treatment. There were no statistically significant differences in QoL scores 
between the two treatment arms and no changes in mean scores during treatment. During the 
last 8 weeks of treatment, a significantly larger portion of patients with radiological response 
reported sustained or better QoL scores than those with no radiological response. 
In Paper III, we investigated the effect of inter physician variation on the delineation of target 
volumes in gastric cancer patients treated with perioperative chemoradiotherapy (CRT).  
Despite the use of a delineation atlas, we found a large variation in CTV and PTV volumes. 
There was only a small variation in target coverage and doses to organs at risk (OARs) in the 
corresponding plans.  In Paper IV, we compared proton therapy to modern photon 
radiotherapy with respect to doses to OARs in gastric cancer patients treated with 
perioperative CRT. Protons offered significantly lower doses to the left kidney, liver, and 
spinal cord, and statistically lower risks for all types and malignant secondary neoplasms 
compared to photons. In Paper V, we evaluated the importance of daily anatomical variations, 
i.e. intestinal gas filling, on the dose distribution of proton beam therapy. The effect of 
intestinal gas variations on the PTV/CTV coverage was large. The sparing effect of protons 
was, however, sustained or the dose to the OARs did not significantly exceed the dose 
delivered with photons. 
In conclusion, sequential chemotherapy and proton radiotherapy are attractive alternatives in 
the treatment of gastric cancer. Standardization of target definitions in CRT, e.g. by reducing 
the inter physician variation, is important and should also be further investigated. 
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1 INTRODUCTION 
1.1  EPIDEMIOLOGY 
Gastric cancer is the fifth most common cancer type worldwide, with almost one million new 
cases diagnosed annually. Due to late detection and remaining therapeutic challenges, the 
case fatality ratio remains at the high 75%. Thus, gastric cancer is the third most common 
cause of cancer related death worldwide, with 9% of cases[1]. The disease is most common 
in parts of Asia, particularly in Japan, China and South Korea, which account for 60% of all 
gastric cancer cases worldwide. It is also relatively common in most Eastern European 
countries and in parts of South America[2, 3].  
Both the incidence and mortality in gastric cancer have decreased during the last few decades 
in a majority of the world’s countries, although local differences appear within regions. As 
late as in 1975, gastric cancer was rated as the most common malignancy worldwide, 
dropping to the fourth most common in 2008[1]. In Sweden, the number of reported cases of 
gastric cancer declined from 2176 in 1970 to 743 in 2012 [4].  
 According to a recently published WHO report on mortality data (1980-2011) and 2003-
2007 Cancer Incidence in Five Continents data[5], the regression of the estimated annual 
percent changes (EAPC) was during recent years -3% for most European countries, Japan 
and Korea and -2% for major countries in North and South America. The EAPC has lately 
shown a trend for lower numbers in most countries, but estimations for 2015 suggest a 
leveling off in both mortality and incidence for some countries, including the US, thus 
breaking the favorable trends seen worldwide since the mid 20th century. 
 
















































































1.2 RISK FACTORS 
The incidence of gastric cancer rises with age, with a worldwide mean age at diagnosis 
between 70-74 years. The disease very rarely occurs before the age of 30. Men are twice as 
often afflicted as women in Asian countries, but this ratio is smaller in Western populations. 
There are no differences between genders in the case fatality rates, i.e. mortality/incidence 
during a specific time period[1].  
The most important risk factor for gastric cancer is Helicobacter Pylori (HP) infection, which 
is estimated to cause approximately 60 - 70% of all cases worldwide[6]. This is thought to be 
a result of a chronic inflammatory process and/or an oncogenic effect of the bacterial 
virulence factor cytotoxin-associated gene A (CagA)[7, 8]. According to a pooled analysis of 
Asian trials, eradication treatment of HP reduces the incidence of gastric cancer[9]. There are, 
however, unexplained variations in the relationship between HP and adenocarcinoma of the 
stomach. In Indian and African populations, both with a high HP infection prevalence, the 
occurrence of gastric cancer still remains low[10].  The HP infection alone is not sufficient to 
cause gastric cancer and the carcinogenesis is thought to be a result of multiple factors[9].  
Other risk factors for gastric cancer include smoking and dietary factors such as low fruit and 
vegetable intake. Furthermore, previous gastric surgery, especially Bilroth II, increases the 
risk[11]. Hereditary predisposition is estimated to account for approximately 10% of all 
cases, with higher risk in families with hereditary non-polyposis colorectal cancer or the 
Peutz-Jegher syndrome.  
The global decrease in gastric cancer incidence has mainly been attributed to the increased 
refrigeration of food and the parallel decrease in dependence on salted or preserved dietary 
products, resulting in intake of fresher foods[1]. Furthermore, decrease in smoking, HP 
eradication, increased sanitation, and in some countries screening programs may explain the 
lower numbers of cases. 
1.3 PATHOPHYSIOLOGY 
The vast majority of gastric tumors are adenocarcinomas (90-95%). Lymphomas and 
carcinoid tumors are unusual[12]. Adenocarcinomas are malignant epithelial tumors, which 
originate from the gastric mucosa and have glandular differentiation. They are divided into 
two main histological subgroups, according to the Lauren classification, i.e. the intestinal type 
and the diffuse type[13]. The carcinogenesis of the intestinal type follows a sequence of 
tissue transformation starting with superficial gastritis, followed by atrophic gastritis, 
intestinal metaplasia, dysplasia, and finally ending with invasive cancer[14]. The 
carcinogenic pathway of the diffuse type remains unclear. There is a predominance of the 
intestinal type in men, elderly patients, and in the high-risk regions, while the diffuse type is 
relatively more common in low-risk countries[15]. The WHO classification is also commonly 
used alongside the Lauren system.  
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Approximately 15% of gastric cancers are located in the fundus, and the remaining ones are 
evenly distributed between the pylorus and corpus. In 10% of the cases the tumor involves 
more than one part of the stomach[16].  The majority of tumors in the gastric corpus are 
located along the major curvature. Adenocarcinoma in the cardia region is generally 
classified as gastric cancer, however, the etiology resembles the one of adenocarcinoma of 
the esophagus[17].  
1.4 PREVENTION AND EARLY DETECTION 
Population screening with gastroscopy, or other methods, e.g. barium meal radiology, differs 
worldwide due to both cost and variations in incidence. There is a long experience of 
screening programs in several Asian countries, foremost in Japan. This is reflected in the 
higher detection rates of early stage gastric cancers of 30-50% compared to 16-24% in 
Western populations[15, 18-20]. In Scandinavia, the incidence of gastric cancer is too low to 
motivate general screening. It can, however, be recommended in high-risk individuals[21]. 
In several Asian countries, HP eradication therapy in accordance to national guidelines has 
been introduced[9]. The efficacy of eradication treatment is, however, highly dependent on 
whether precancerous lesions are present. Due to limitations in present eradication treatment 
and the multifactorial nature of carcinogenesis, general treatment, other than in high-risk 
individuals, is not recommended in European guidelines[22, 23].   
1.5 CLINICAL PRESENTATION 
The clinical manifestations and the findings at the physical examination are often unspecific 
and overlap with common non-malignant diseases. This frequently results in late diagnosis. 
In Western countries, around two-thirds of the patients with gastric cancer present with 
advanced disease[24, 25]. Early symptoms include upper abdominal discomfort or a dull and 
unspecific pain, which is often combined with dyspepsia. Typically, these symptoms initially 
respond to antipeptic treatment, which may further delay the diagnosis. As the tumor 
progresses, additional symptoms such as anorexia, nausea, and weight loss may appear.  
Proximal tumors in the cardia are often associated with dysphagia, while the ones close to the 
pylorus or antrum may lead to gastric outlet obstruction syndrome associated with nausea and 
vomiting. Tumors infiltrating large portions of the gastric wall affect the ability for distention, 
which results in early satiety. Gastric bleeding occurs with variable intensity but melena has 
been reported in only one-fourth of the patients[24]. However, patients with unexplained 
iron-deficiency anemia should be liberally referred for an endoscopic examination. Physical 
findings on examination may include an abdominal mass, ascites, or palpable, typically 
supraclavicular or periumbical nodes. These are all, however, signs of locally advanced 
and/or metastatic disease. 
Biochemical markers, e.g. carcinoembryonic antigen (CEA), CA125, CA19-9, CA72-4 and 
α-fetoprotein, are elevated in 15-60% of patients[26, 27]. They are, however, not specific for 
gastric cancer and are, thus, presently of limited value in the diagnostic situation. Elevated 
CEA and CA72-4 levels at diagnosis are associated with poor outcome[28, 29]. 
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1.6 DIAGNOSTICS AND STAGING 
Endoscopy is the most sensitive and specific diagnostic method for detecting gastric cancer. 
This examination should include the esophagus, the stomach, and the duodenum. The 
sensitivity of endoscopy in early gastric cancer is not well studied, but according to Japanese 
data, a substantial amount of lesions can be missed[30]. A histological sensitivity of over 
98% can be reached if at least 7 biopsies are obtained[31]. The T stage and the Borrmann 
classification of the tumor are obtained with the endoscopic evaluation of the growth pattern 
in combination with histological analysis of the depth of invasion, possibly assisted by an 
endoscopic ultra sound examination. Other radiological methods have not yet been shown 
reliable as means for T-staging other than detecting a thickening of the gastric wall and direct 
tumor invasion into surrounding tissues. Computer tomography scanning detects 26-56% of 
early gastric tumors and correctly evaluates wall invasion in only 15% of these cases. 
Detection rates in advanced gastric cancer are higher, i.e. 88-100% [32, 33]. Dedicated CT 
scans are reliable for predicting tumor resectability[34] and the evaluation of bulky disease. 
T-stage evaluation with modern MRI techniques is promising but still remains 
investigational. 
Most commonly, CT is used for N-staging. However, the method’s specificity and sensitivity 
for detecting metastatic lymph nodes are widely questioned. This is due to the fact that the 
diagnosis of pathological nodes is based on nodal size only, rendering an accuracy of 25 to 
70% in different series[35]. Endoscopic ultra sound, especially when combined with fine 
needle aspiration cytology, is more sensitive for detecting nodal metastases in the proximity 
of the stomach than CT alone and can be used as a complementary technique[36]. The risk of 
involvement of regional lymph nodes increases with the depth of tumor penetration in the 
gastric wall[37]. Lymph node involvement is reported in 3-5% of tumors confined to the 
mucosa, in 11-25% of those extending to the submucosa, in 50% of those reaching the 
muscularis, and finally, in 83% of those involving the serosa[38, 39].   
The most widely used radiological modality for detection of distant metastases (M-staging) is 
CT, with a reported sensitivity rate of 90%[40]. Routinely, the examination includes the 
lower neck, the thorax, and the abdomen. Brain metastases are uncommon and CT of the 
brain has therefore not been considered cost-effective. Positron emission tomography with 
fluorodeoxyglucose (FDG-PET) has a superior sensitivity in detecting distant metastases 
compared to CT[41]. However, MRI, and possibly contrast-enhanced ultrasonography 
(CEUS), have been reported to have higher sensitivity than FDG-PET in detecting liver 
metastases[42, 43]. Furthermore, it remains uncertain whether CT or PET-CT is more reliable 
in detecting peritoneal metastases[44]. 
Parallel to the staging process, a careful evaluation of the patients’ general physical condition 
should be undertaken, due to the high intensity and toxicity of the treatments. A detailed 
patient history and physical examination should be performed and, if necessary, additional 
evaluations of the heart, lung, and kidney functions. 
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Primary	  tumor	  (T)	  
TX	   Primary	  tumor	  cannot	  be	  assessed	  
T0	   No	  evidence	  of	  primary	  tumor	  
Tis	   Carcinoma	  in	  situ:	  intraepithelial	  tumor	  without	  invasion	  of	  the	  lamina	  propria	  
T1	   Tumor	  invades	  lamina	  propria,	  muscularis	  mucosae,	  or	  submucosa	  
T1a	   Tumor	  invades	  lamina	  propria	  or	  muscularis	  mucosae	  
T1b	   Tumor	  invades	  submucosa	  
T2	   Tumor	  invades	  muscularis	  propria	  
T3	   Tumor	  penetrates	  subserosal	  connective	  tissue	  without	  invasion	  of	  visceral	  peritoneum	  or	  adjacent	  structures	  
T4	   Tumor	  invades	  serosa	  (visceral	  peritoneum)	  or	  adjacent	  structures	  
T4a	   Tumor	  invades	  serosa	  (visceral	  peritoneum)	  
T4b	   Tumor	  invades	  adjacent	  structures	  
Regional	  lymph	  nodes	  (N)	  
NX	   Regional	  lymph	  node(s)	  cannot	  be	  assessed	  
N0	   No	  regional	  lymph	  node	  metastasis	  
N1	   Metastasis	  in	  1-­‐2	  regional	  lymph	  nodes	  
N2	   Metastasis	  in	  3-­‐6	  regional	  lymph	  nodes	  
N3	   Metastasis	  in	  seven	  or	  more	  regional	  lymph	  nodes	  
N3a	   Metastasis	  in	  7-­‐15	  regional	  lymph	  nodes	  
N3b	   Metastasis	  in	  16	  or	  more	  regional	  lymph	  nodes	  
Distant	  metastasis	  (M)	  
M0	   No	  distant	  metastasis	  
M1	   Distant	  metastasis	  
Table 1. TNM-staging for gastric cancer. 
1.7 PROGNOSIS 
The prognosis for the general population of patients with adenocarcinoma of the stomach and 
the gastroesophageal junction is poor. Furthermore, it is highly dependent on tumor stage and 
localization, patient age, and comorbidity. Patients with tumors confined to the mucosa and 
submucosa layers of the stomach have 5-year survival rates of 86% following surgical 
gastrectomy[1, 45]. This number drops dramatically when the tumor extends through the 
gastric wall and/or metastasizes to the regional lymph nodes, i.e. 5-year survival rates of 
30%[45, 46]. 
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There are large geographical differences in 5-year survival rates between Eastern Asia and 
the Western countries, i.e. 20-30% in Europe and the US compared to 40-60% in Japan[1, 46, 
47]. These differences have been attributed to variations in the proportion of early gastric 
cancers at the time of diagnosis, tumor biology, and localization[48].  Between 1995 and 
2000, the proportion of patients with early gastric cancer at the time of diagnosis in Eastern 
Asia was 53% compared to 14-20% in Western populations[49]. In a population based 
European report, the majority of gastric cancer patients presented with irresectable or 
metastatic disease. The curative resection rate was less than 50% and 5-year survival rates 
were 28-42%[50].    
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2 TREATMENT 
2.1 CURATIVE TREATMENT 
Until recently, radical surgery was the only hope for cure in gastric adenocarcinoma of the 
stomach and the gastroesophageal junction. However, the high rates of relapse after resection 
led to an interest in more effective strategies.  The different methods used were: 
1. Altered, more radical surgical techniques 
2. Combination of chemotherapy with surgery 
3. Combination of chemoradiotherapy with surgery 
2.1.1 Surgery 
2.1.1.1 Gastric resection 
Curative treatment always involves a tumor resection with a subtotal or total gastrectomy. 
The decrease in incidence of gastric cancer combined with a decrease in benign gastric 
surgery during the last decades of the previous century, have high-lighted the necessity for 
concentrating surgery in these patients to high-volume centers. Today, the subtotal resection 
is used routinely in the majority of patients with intestinal type gastric cancer in the distal or 
mid portion of the stomach, in which a margin of at least 2 cm, and preferably larger, can be 
obtained[51-54]. In patients with proximal tumors, a total gastrectomy is commonly 
performed with resection of the distal portion of the esophagus. In the diffuse type gastric 
cancer, a R0 situation is difficult to achieve with limited surgery and thus total gastrectomy is 
generally recommended. This procedure is followed by a construction of a gastric reservoir in 
order to minimize the postoperative weight loss due to low calorie intake and losses through 
diarrhea, and to improve the postoperative quality of life [55, 56]. The reconstruction can be 
achieved by a long Roux-en-Y esophagojejunostomy. 
2.1.1.2 Lymphadenoectomy 
A major point of discussion in terms of gastric cancer surgery has been the extent of lymph 
node dissection.  The Japanese Gastric Cancer Association (JGCA) defined 16 nodal stations 
commonly involved in the lymphatic drainage of the stomach[57]. These stations are further 
divided into three levels of increasing distance to the stomach, and thus defining the extent of 
nodal resection (D1-3) (Table 2). Several prospective randomized trials have investigated the 
effect of a more extensive lymphadenectomy (D2) compared to the standard D1 resection, in 
which only the perigastric lymph nodes are removed. The Dutch Gastric Cancer Group trial, 
including 711 patients, did not show any difference in survival, but significantly higher 
operative mortality and morbidity in the extended resection group[58]. A later subgroup 
analysis showed a trend for better survival among N2-positive patients in the D2 group. 
These results were confirmed by the British MRC trial[59]. In both trials, the increases in 
complication rates were thought to be associated with the pancreatoectomy and/or 
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splenectomy rather than the extent of the lymphadenoectomy. However, in a later, European 
study with a higher grade of centralization of surgery no difference in morbidity was found 
between D1 and D2[60]. A highly centralized trial from Taiwan, comparing D1 and extended 
D2 resections, reported no perioperative mortality and higher 5-year survival in the extended 
resection group[61].  
Regional lymph node stations  
No. 1 Right paracardial LN 
No. 2 Left paracardial LN 
No. 3 LN along the lesser curvature 
No. 4 LN along greater curve (short gastric vessels, left and right gastroepiploic vessels) 
No. 5 Suprapyloric LN 
No. 6 Infrapyloric LN 
No. 7 LN along the left gastric artery 
No. 8 LN along the common hepatic artery (anterosuperior and posterior group) 
No. 9 LN around the celiac artery 
No. 10 LN at the splenic hilum 
No. 11 LN along the splenic artery (proximal and distal tract) 
No. 12 LN in the hepatoduodenal ligament (along hepatic artery, bile duct and portal vein) 
No. 13 Retropancreatic LN 
No. 14 LN along superior mesenteric vessels (vein and artery) 
No. 15 LN along the middle colic vessels 
No. 16 LN paraaortic (of upper, middle and lower abdominal aorta, in relation to the intragastric        
tumor site) 
The classification includes also the following lymph node compartments:  
No. 17 LN on the anterior surface of the pancreatic head 
No. 18 LN along the inferior margin of the pancreas 
No. 19 Infradiaphragmatic LN 
No. 20 LN in the esophageal hiatus of the diaphragm 
No. 110 Paraesophageal LN in the lower thorax 
No. 111 Supradiaphragmatic LN 




Table 2. Regional lymph nodes according to the Japanese Research Society for Gastric 
Cancer (1998) and corresponding levels of surgical dissection. LN = lymph nodes. 
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In conclusion, in the Asian countries, with high rates of incidence and high volumes of gastric 
cancer patients operated by specialized surgeons, D2 lymphadenoectomy is considered as 
standard procedure. In Western countries, with low incidence and, thus, fewer cases per 
center the question of D1 vs. D2 resection remains to some extent unresolved[62].  However, 
after the report of 15-year follow up from the Dutch Gastric Cancer Group, which showed a 
lower rate of locoregional recurrence and gastric-cancer-related death with D2 resections 
compared to D1[63], the extended lymphadenoectomy is becoming the preferred procedure 
even in Western countries. 
2.1.2 Adjuvant therapies 
Local recurrences after radical gastric cancer surgery occur in 40-60% of the patients, both as 
the only site of disease recurrence and as a part of a disseminated disease[64]. The most 
frequently involved sites of recurrence include the areas previously occupied by the tumor, 
the regions in the proximity of the anastomoses and the non-resected regional lymph nodes. 
This fact suggests that surgery, as a single modality treatment, cannot fully address the 
microscopic tumor residues around the primary site and those disseminated during the 
operative procedure, thus creating a rationale for systemic and radiation therapy. A recent 
review on the extent of lymphadenectomy suggested, that surgery has reached or almost 
reached its full potential as a curative treatment in gastric cancer and further development 
should be pursued in non-surgical perioperative treatment modalities[62]. 
2.1.2.1 Postoperative chemotherapy 
There are many published randomized controlled clinical trials on adjuvant postoperative 
chemotherapy. In later years some trials also combined chemotherapy with immunotherapy. 
Various regimens were investigated and many of the early chemotherapy combinations are 
today considered outdated. Only a few trials managed to demonstrate any benefit in survival 
for adjuvant chemotherapy compared to surgery alone[65, 66] and none in a Western 
population[67]. In meta-analyses of trials conducted in a Western population, no 
improvement of survival was detected[67-69]. However, in the Asian CLASSIC trial with 
1035 patients, adjuvant chemotherapy with capecitabine in combination with oxaliplatin 
significantly increased 3-year survival compared to surgery alone (74% vs. 59%, 
p<0.0001)[66]. Another recent large Japanese randomized trial of adjuvant S-1 demonstrated 
a 3-year survival rate of 80.1% in the surgery plus S-1 group compared to 70.1% in the 
surgery only group (p=0.003)[65]. These results have not been replicated in a Western 
population. S-1 has not been registered in the US due to high toxicity in a Caucasian 
population. The latter data raise the question of patient ethnicity and different response to 
treatment as well as variations in tumor biology of gastric cancer in Asian and Western 
populations. In conclusion, the role of adjuvant chemotherapy in gastric cancer in a Western 
population remains unclear and a subject of further investigation. 
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2.1.2.2 Postoperative radiotherapy 
In a trial by the British Stomach Cancer group, 436 patients were randomized between three 
treatment arms: surgery alone, surgery with chemotherapy (FAM), or surgery with 
radiotherapy (RT) to 45-50 Gy. The trial failed to show any survival differences between the 
three arms[70]. 
2.1.2.3 Perioperative chemotherapy 
Perioperative chemotherapy, a commonly used strategy in Europe, was introduced due to the 
results of two major randomized trials. Firstly, the British MAGIC trial randomized 500 
resectable Stage ≥ II gastric or distal esophageal adenocarcinoma patients to surgery alone or 
surgery plus pre- and postoperative chemotherapy with epirubicin, cisplatin and 5-Fu[71]. 
There was a significantly improved 5-year survival (36% vs. 23%, p= 0.009), progression-
free survival, and decreased tumor size and stage in the perioperative chemotherapy group. It 
is, however, worth noticing that only 42% of all patients completed the entire treatment. The 
main reasons for not proceeding with the postoperative chemotherapy were disease 
progression or patient choice. Secondly, the French ACCORD07/FFCD-9703 trial[72] 
randomized 224 patients to either surgery alone or surgery with perioperative chemotherapy, 
i.e. cisplatin and 5-Fu.  The 5-year disease-free survival was significantly better in the 
combined treatment arm, 34% vs. 21%. Furthermore, chemotherapy significantly improved 
the curative resection rate, 84% vs. 73%. 
2.1.2.4 Perioperative targeted therapy 
Several case reports with trastuzumab containing preoperative chemotherapy regimens in 
HER2 positive gastric cancer have been published with promising outcomes[73, 74]. 
Following the results in colorectal cancer, bevacizumab, a monoclonal antibody targeting the 
vascular endothelial growth factor, has been included in trials of gastric cancer. In the 
AVAGAST trial, the addition of bevacizumab in first line therapy in advanced gastric cancer 
patients showed no improvement in overall survival, but prolonged progression-free survival, 
and response rates[75]. The British MAGIC B trial is accruing patients to compare 
perioperative chemotherapy with or without bevacizumab in patients with resectable gastric 
cancer. 
2.1.2.5 Perioperative chemoradiotherapy 
Trials investigating chemoradiotherapy (CRT) in gastric cancer have been reported since the 
nineteen-eighties. One of the first randomized trials on this subject was published in 1984. 
Although small, the authors reported a staggering difference in 5-year survival of 4% vs. 23% 
between patients treated with surgery only (n=23) and surgery followed by 5-Fu in 
combination with RT (n=39)[76]. 
The efficacy of cisplatin and 5-Fu in gastric cancer is well established[77] and the 
mechanisms of synergy between these drugs and RT are also well described. Cisplatin 
inhibits the repair of radiation-induced injury and directly enhances DNA injury by formation 
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of DNA-adducts. In the case of 5-Fu, it has been suggested that RT sensitizes the cells to the 
DNA interfering effect of the drug[78, 79].  
 Since the publication of the results of the Intergroup 0116 trial in 2001, the combination of 
chemotherapy and RT has become the routine treatment after radical resection of gastric 
cancer in the United States[80]. In this study, 556 patients with resectable Stage ≥ II disease 
were randomized between surgery only and surgery followed by CRT. The latter, 
experimental arm consisted of chemotherapy with three courses of 5-Fu perioperatively and 
two shortened courses during RT (45 Gy in 25 fractions in five weeks). Radiotherapy 
planning was 2-D based. The results were highly encouraging; with an increase of median 
overall survival from 27 to 36 months and the disease-free survival from 19 to 30 months in 
the CRT arm. This study has, however, been heavily criticized on several points, and CRT 
has not become the standard treatment in Europe. In more than 50% of cases the extent of the 
surgical procedures was ruled as less than a D1 resection suggesting that the additional 
treatment only compensated for suboptimal surgery. The rationale for this criticism can be 
put into question in the light of the results in rectal cancer, where the relative effect of CRT 
becomes more pronounced when more adequate surgery is performed. Furthermore, the 
patients included in the Intergroup 0116 trial had an increased risk of relapse due to higher 
disease stage (more than two thirds had a T3 or T4 tumor and 85% were node positive) than 
patients in most published surgical series. Additionally, there was a considerable toxicity in 
the CRT arm, resulting in 54% hematological and 33% gastrointestinal Grade III or IV 
toxicity. This resulted in only 62% of the patients completing the entire treatment. A 
considerable part of the toxicity was considered due to the use of an outdated chemotherapy 
regimen and radiotherapy technique. The updated results on the Intergroup 0116 trial were 
published in 2009[81] and 2012[82] after a median follow up time of over ten years. The 
overall and disease free survival (p=0.001) as well as recurrence rates (p<0.001) were still 
significantly better in the experimental arm.  
The role of perioperative CRT in relationship to the extent of lymphadenectomy was 
addressed in a Korean observational trial of 1000 patients after a R0 D2 gastric resection, 
which was published in 2005[83]. Five hundred and forty-four patients received similar 
postoperative CRT as in the Intergroup 0116 trial, while the control group of 446 patients had 
no additional treatment. The two groups differed by higher rates of undifferentiated 
carcinomas (p=0.0021), Stage IIIA (p=0.005), and Stage IV (p=0.0011) in the CRT arm. 
Despite the difference in the patient populations, the median overall survival (95.3 vs. 62.6 
months) and disease-free survival (75.6 vs. 52.7 months) were significantly better in the CRT 
arm. Seventy-five percent of the patients completed the entire treatment protocol in the CRT 
arm. 
A meta-analysis including five randomized clinical trials and 868 patients investigated the 
benefit of perioperative CRT compared to surgery alone[84]. The CRT group had a 
significantly lower overall risk for mortality than the control group (p=0.00001). The protocol 
completion rate was 73.3%. 
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In the ARTIST trial[85], including 458 patients, the authors compared perioperative 
chemotherapy with perioperative CRT after D2 gastric resection. No statistically significant 
differences were found in the recurrence rate or the 3-year disease-free survival (78.2% in 
CRT group vs. 74.2%, p=0.086). However, a significantly longer disease-free survival was 
found in the CRT arm among patients with node positive disease (77.5% vs. 72.3%, 
p=0.035).   
Presently, two large ongoing multicenter trials, the European CRITICS trial (CRITICS; 
clinicaltrials.gov NCT 00407186) and the Australian TOP-GEAR trial (TOP-GEAR; 
clinicaltrials.gov NCT 01924819) address the role of perioperative CRT in gastric cancer. 
Furthermore, since the publication of the Intergroup 0116 trial, the concept of CRT has been 
better established in several other diagnoses, e.g. rectal, head-neck and lung cancers. 
2.2 PALLIATIVE TREATMENT 
At the time of diagnosis, the majority of gastric cancer patients in the Western countries, 
present with irresectable and/or metastatic disease. Furthermore, many patients previously 
treated with curatively intended gastric resection recur. In these patients, palliative treatment 
is of importance to control tumor related symptoms and to improve survival while preserving 
or preferably improving quality of life (QoL).  
The symptoms of locally advanced and/or metastatic disease are both of general and local 
nature and vary among individuals. While chemotherapy has the potential to alleviate general 
symptoms, surgery and radiotherapy can be used to treat local symptoms caused by 
obstruction or tumor overgrowth. 
2.2.1 Surgery 
Endoscopic stent treatment is by far the most common method of surgical palliation in gastric 
cancer. Tumors located in the distal portion of the esophagus, the cardia or the proximal 
portion of the stomach, often cause inadequate nutritional intake and swallowing problems. 
Stent treatment is both safe and more effective than nasogastric sond nutrition in terms of 
avoiding weight loss. This facilitates the initiation of oncological treatment and stabilizes 
serum albumin levels[86]. Severe gastric outlet obstruction syndrome, typically leading to 
nausea, vomiting and inadequate nutritional intake, can also be treated with surgical open or 
laparoscopic gastroenteroanastomosis. Stent treatment is, however, less invasive and, thus, 
less strenuous for the patient. It is, however associated with higher frequency of re-
obstruction and lower long-term nutritional intake and predominantly the treatment of choice 
for patients with short expected survival[87, 88].   
2.2.2 Chemotherapy 
Patients with metastatic, inoperable, or recurrent gastric cancers have a median survival time 
of 3 - 5 months with only best supportive care (BSC). Randomized trials have shown that the 
median survival time in this patient group can be prolonged by 4 – 6 months with 
chemotherapy compared to BSC alone[89-91], but the benefit has to be weighed against 
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treatment-induced toxicity. The most commonly used combinations contain either continuous 
infusion or bolus 5-fluorouracil (5-Fu), or oral capecitabine.  In addition, the drugs cisplatin, 
doxorubicin or epirubicin, etoposide, and more lately irinotecan, docetaxel and oxaliplatin 
have been used in various combinations[67, 77]. In the Cochrane meta-analysis from 
2010[77], combinations of two or three cytostatic drugs had a survival benefit (HR 0.86) 
compared to single agent treatment, but resulted only in a further modest increase of 2 
months in time to progression (TTP) and 1.5 months in overall survival, and in increased 
toxicity and risk of toxic death (HR 1.22). The meta-analysis by the GASTRIC group 
concluded that the addition of any new chemotherapeutic agent to the standard control 
regimen resulted in slight improvements in overall and progression free survival, this effect 
being foremost visible for cisplatin and irinotecan[92]. 
Despite a multitude of performed randomized trials and meta-analyses, there is no 
international consensus on the optimal regimen in palliative therapy of gastric cancer[93]. 
This is due to inter trial variations in study populations and the lack of head-to-head 
comparisons for all used combinations. In the routine treatment, double or triple 
combinations are generally recommended. In Sweden, patients with good performance status 
were previously treated with a combination of etoposide and 5-Fu (ELF)[91], while elderly 
patients or those with poor performance status received single agent bolus 5-Fu. Superior 
response rates have, however, been reported for the irinotecan/5-Fu/leucovorin (ILF) 
combination compared to the ELF regimen (35% vs. 17%). Internationally, cisplatin based 
double or triple combinations have previously been dominating, i.e. epirubicin/cisplatin/5-Fu 
(ECF)[94] and cisplatin/5-Fu (CF). More aggressive combinations have also been studied, i.e. 
in the phase III TAX325 trial[95]. The authors of the latter article reported that the 
combination of cisplatin, docetaxel and 5-Fu (DCF) increased median survival, 10.2 vs. 8.5 
months, and response rates, 39% vs. 23%, compared to CF. There was, however, a 
considerable amount of toxicity associated with the triple combination, e.g. Grade 3-4 
toxicity present in 69% of cases and complicated neutropenia in 29%. 
The dominating role of cisplatin in the treatment arsenal for gastric cancer was questioned 
after the publication of the British REAL-2 trial[96]. This four-arm study demonstrated the 
equivalence of oxaliplatin to cisplatin and capecitabine to infusion 5-Fu. The latter 
relationship was also confirmed in another controlled trial[97]. Furthermore, a Cochrane 
meta-analysis[77] reported that anthracyclines had an effect in gastric cancer independent of 
platinum based therapy.  A recently published meta-analysis reported improved response 
rates and outcome in drug combinations where cisplatin was replaced with irinotecan, 
oxaliplatin, or taxanes compared to cisplatin based double or triple combinations[98].  This 
analysis failed, however, to identify the subgroups of patients who would gain most from 
cisplatin-free therapy.  
2.2.2.1 Irinotecan 
The efficacy of irinotecan, a topoisomerase 1 inhibitor, has been evaluated in gastric cancer 
both as single agent and in combinations. As a single agent, response rates of 23% have been 
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reported[99], which is comparable to other drugs with activity in this disease. In gastric 
cancer irinotecan is mostly combined with either 5-Fu or cisplatin. A response rate of 23% 
and a median survival of 6.3 months have been reported for the combination of irinotecan and 
5-Fu[100]. Response rates of 31-58% have been reported for the combination irinotecan and 
cisplatin, with a feasible toxicity profile and with median survival of 5-10.7 months[101-
104]. In a randomized phase II study, ILF yielded higher response rates (35% vs. 17%, n = 
104) than the classical ELF-regimen, which previously was frequently used in Sweden[105]. 
Another randomized phase II study compared irinotecan in combination with fluorouracil to 
irinotecan in combination with cisplatin, and demonstrated an overall response rate of 34% 
and 28% respectively and a median survival of 10.7 months vs. 6.9 months. Thus, a superior 
efficacy was shown for the less toxic cisplatin-free combination[106]. Furthermore, 
irinotecan has been reported effective in second line palliative treatment of gastric cancer 
compared to BSC after previous tumor progression on cisplatin-based regimens[107]. 
2.2.2.2 Docetaxel 
As single agent, docetaxel yields response rates of 17-24% in first line treatment of advanced 
gastric cancer[108, 109]. The most common docetaxel combinations include 5-Fu and/or 
cisplatin. Docetaxel in combination with cisplatin has produced response rates of 37-56%, 
while docetaxel in combination with 5-Fu has shown response rates of 28-86%[110-112]. A 
phase II study compared docetaxel in combination with cisplatin (TC) to docetaxel in 
combination with 5-Fu and cisplatin (TCF) with response rates of 35 vs. 54% and median 
survival 10.5 vs. 9.6 months, respectively. There were more gastrointestinal toxicities with 
4.3% diarrhea in the TCF arm compared to 1.2% in the TC arm. Neutropenia was more 
common in the TCF arm with 59.6% vs. 49% in the TC arm. Noticeably, 2.5% of the patients 
in the TCF arm died due to febrile neutropenia[113]. The results of the large controlled trial 
TAX 325, in which the triple combination docetaxel, cisplatin, and 5-Fu was compared to 
cisplatin and 5-Fu, is discussed above (section 2.2.2). 
2.2.2.3 Sequential chemotherapy 
Combinations of several drugs, thus, result in higher response rates than single drug 
treatment, but are generally more toxic. There is a lack in convincing evidence of clinical 
benefit in terms of improved QoL, when multiple drug combinations are used rather than 
sequential treatment, even if subgroups of patients are likely to benefit from the most 
aggressive upfront therapy. Furthermore, according to the Goldie and Coldman hypothesis, 
using active drugs in a predefined alternating sequence, may reduce the risk of inducing drug 
resistance[114]. This hypothesis is based on a mathematical model relating the drug 
sensitivity of a tumor to its own spontaneous mutation rate towards phenotypic drug 
resistance. According to this model, the proportion as well as the absolute numbers of 
resistant cells will increase with time and the fraction of resistant cells within tumor colonies 
of the same size will vary depending on whether mutation occurs early or late. The 
probability of the appearance of a resistant phenotype increases with the mutation rate. 
Furthermore, for any population of tumors with a non-zero mutation rate the likelihood of 
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there being at least one resistant cell will go from a condition of low to high probability over 
a very short interval in the tumor's biologic history. 
Sequential chemotherapy may allow the delivery of a greater number of drugs, the dose of 
each drug to be optimized, and limitation of toxicity. In a sequential schedule, the evaluation 
of the response to each drug or drug combination, in order to identify the most active drug(s) 
as an in vivo chemo sensitivity test, may potentially guide the selection of individually 
tailored consolidation or maintenance chemotherapy. In addition, the “worst drug rule” can 
be applied[115]. According to this rule, in order to kill clones resistant to the most active 
regimen when two non-cross-resistant regimens are available with different activities, the less 
active regimen should be administered first. However, the dismal outcome and the rapid 
deterioration observed in patients with advanced gastric cancer following first line 
chemotherapy do not support the application of the “worst drug rule” in this setting. 
The concept of sequential chemotherapy has, to some extent, been used in palliative breast 
cancer treatment and has now become a part of the routine chemotherapy arsenal in the 
adjuvant setting[116]. A recently published Cochrane meta-analysis[117], found twelve 
randomized trials, with a total of 2317 patients, comparing combinations of drugs to the same 
drugs used in a sequential setting in first, second, and third line treatment in metastatic breast 
cancer. The authors did not find any difference in survival (p=0.45) according to how the 
treatment was given. Furthermore, the risk of progression was significantly higher in the 
combination group (p=0.01), as were the response rates (p=0.001). The latter difference was, 
however, largely heterogeneous between the analyzed trials. The risk of febrile neutropenia 
was higher in the combination group (p=0.01), but no statistically significant differences were 
found regarding neutropenia, nausea, vomiting, or treatment related deaths. There were also 
no differences in QoL, but this had been reported in only three of the twelve trials. Similar 
results, with lower toxicity and lack of differences in survival for sequential treatment 
compared to combination treatment, have been reported in other malignant diseases, i.e. 
colorectal cancer[118] and in lymphoma[119]. 
2.2.3 Quality of life 
Despite increased response rates, the median survival of patients with advanced gastric cancer 
remains low, rarely exceeding 10 months, even with triple combinations of cytotoxic drugs or 
with the addition of biological agents. Due to the poor prognosis of this patient population 
and relatively limited and similar gains in median OS with the use of various cytotoxic 
therapies, it is important to evaluate the effect of any new anticancer treatment not only on its 
life prolonging ability but also on the QoL. This fact has been given increasing attention 
during the last decade, driven by the development of the toxic double and triple drug 
combinations. As most patients with advanced gastric cancer are not cured and many 
regimens have similar efficacy, differences in QoL may help to determine which regimen is 
preferred. Several authors suggested that QoL measurement should be used as an independent 
measure in evaluating the outcome of new treatments[120] and the American Society of 
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Clinical Oncology recommended already in its 1996 guidelines that survival and QoL are of 
more importance in evaluation of efficacy than response rates and biomarker changes.  
In a review of 19 trials in advanced gastric cancer[121], the authors reported that no 
significant gain in QoL was obtained with chemotherapy. Scores were maintained for 
approximately half of the patients for a period of six months but deteriorated for the 
remaining patients. The effect of therapy on QoL appeared to be connected with the objective 
treatment response rather than with the toxicity. In three of the randomized phase III trials, 
cisplatin/5-Fu in combination with either docetaxel or epirubicin improved QoL scores 
compared to the control groups. 
In the updated Cochrane analysis of chemotherapy in advanced gastric cancer[77], QoL is 
one of the main variables reported when comparing treatments. However, many randomized 
clinical trials still do not report outcomes in QoL, which limits the possibility of analyzing 
QoL in an adequate meta-analysis. Furthermore, studies assessing QoL in tumors of the upper 
gastrointestinal tract have often reported poor accrual and poor collection rates of the QoL 
assessments[94, 122, 123]. Consequently, poor compliance and reporting of the QoL data 
might bias and influence the conclusions[124]. Attempts to improve compliance have focused 
on improvement of assessment tools, i.e. questionnaires, and on computer-based methods of 
reporting and have led to encouraging results[125, 126]. 
The most commonly used QoL assessment tool is the European Organization for Research 
and Treatment of Cancer core questionnaire (EORTC QLQ-C30). It is used worldwide and 
for a large number of malignant diagnoses[127]. The Swedish version of the EORTC QLQ-
C30 has been validated [128]. This questionnaire has been further developed to include site-
specific modules for better evaluation of anatomically relevant complaints, including a 
module for gastric- (QLQ-STO22) and esophageal cancer (QLQ-OES18). Both modules have 
been internationally validated[129, 130].  There are alternative questionnaires for assessment 
of QoL, i.e. the SF-36[131]. The advantage of the EORTC QLQ-30 is, however, its cancer- 
and site-specificity in combination with the high grade of validity and popularity, which 
increases the comparison reliability.  
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3 RADIOTHERAPY IN GASTRIC CANCER 
Radiotherapy (RT) may be an important treatment modality for patients with gastric cancer, 
especially in the adjuvant setting. Its role in this patient group has been in the perioperative 
setting in combination with chemotherapy (CRT), as described above (section 2.1.2.5), and is 
now also the subject of two large multicenter trials, i.e. the European CRITICS and the 
Australian TOPGEAR trials. In gastric cancer irradiation, generally doses of 1.8 Gy per 
fraction to a total dose of 45 Gy are used, to treat potential residual microscopic disease[80, 
132]. The position of CRT as standard treatment in the United States is based on the results of 
the previously described Intergroup 0116 trial[80], a trial that has received criticism for its 
outdated planning techniques and consequently considerable toxicity. In this trial, two 
dimensional (2D) treatment planning was used, and two opposed antero-posterior, posterior-
anterior photon beams, with an attempt to spare one of the kidneys from incidental 
irradiation. Since the start of enrollment in this trial in 1991, the development and 
implementation of new irradiation techniques has been a fast growing field. This includes 
progress in treatment planning, methods of patient immobilization, and compensation for 
patient movement by image guided RT. 
3.1 PHOTON TECHNIQUES 
During the 1990-ies, 3D conformal RT became the standard RT technique. This planning 
strategy requires planning capabilities such as 3D target and organs at risk (OARs) volume 
definition.  Structures of interest are delineated on cross-sectional images (CT, MRI, or PET) 
on a slice-by-slice basis as opposed to drawing beam portals on a simulator radiograph, which 
was used in 2D planning. The treatment plan is further constructed by the application of a 
number of fields shaped by multi leaf collimators (MLCs) and their fluence can be further 
optimized by the addition of wedges and physical modulators, i.e. compensation filters. These 
modifications are performed manually in a planning system, thus making this method of 
planning highly sensitive to the individual creativity and experience of the dose-planner. 
The 3D conformal RT planning has been further developed, resulting in the intensity 
modulated radiotherapy (IMRT) planning technique[133], which has been increasingly 
adopted into standard RT since the late 1990-ies. It is based on inverse treatment planning, 
where an interactive computer optimization algorithm calculates for all given beam 
directions, the optimal fluence profiles necessary to obtain the desired dose distribution 
within the patient. The fluence of each beam is shaped through the continues movement of 
the MLCs during irradiation[134] and the resulting plan shows higher levels of dose to target 
conformity. Further developments of IMRT include the rotational irradiation techniques such 
as volumetric modulated radiotherapy (VMAT) and tomotherapy, where dose delivery is 
modeled by infinite number of beam directions and a variable dose-rate combined with 
continues MLC movement, providing shorter or longer treatment times, respectively, with 
equal or enhanced conformity[135].  However, both IMRT and the rotational techniques 
demand larger amounts of monitor units (MUs) and, consequently, the delivery of the same 
dose to the target results in a higher integral dose to the patient. This is seen as large volumes 
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of “low-dose-bath” in the patient and it may potentially lead to an increased risk of treatment-
induced secondary neoplasms.  
A dose planning trial comparing 3D conformal RT with nine-field IMRT in gastric cancer 
revealed satisfactory coverage of the clinical target volumes by the 95% iso-dose with either 
technique. Furthermore, IMRT was only marginally better than 3D-RT at protecting the spine 
and kidneys from incidental radiation[136]. This suggests that only a small subgroup of 
patients would benefit clinically from more advanced planning techniques. However, a 
recently published Dutch trial[137], which compared 2D planning technique according to the 
Intergroup 0116 trial to 3D-conformal and IMRT in 87 gastric cancer patients, found a 
significantly lower dose to the left kidney for the IMRT plans. This difference was also 
shown to be of clinical significance, as the kidney function was decreasing in the total 
population, but at a lower rate in patients treated with IMRT, thus establishing a dose-effect 
relationship for the left kidney function. Of the 87 patients, 6 developed hypertension, but 
none in the IMRT group at the median follow up time of 4.7 years. In a recent retrospective 
analysis, adjuvant CRT with IMRT and modern chemotherapy doublets led to better survival 
in patients with advanced gastric cancer compared to the adjuvant combination of 3D 
conformal RT and conventional chemotherapy, also in the long- term follow-up[138]. This 
may be an effect of the compromise between kidney sparing and PTV coverage in 2D and 3D 
conformal RT planning, which can be avoided in IMRT. 
3.2 PROTON TECHNIQUES 
The possibility to use proton radiotherapy (PT) for medical purposes was suggested already 
in 1946[139] and in 1954 the first patient was treated for a pituitary disorder. Since that year, 
several laboratories, among them the Svedberg Laboratory in Uppsala, continued to treat 
patients with protons (and/or ions) on a small scale. Today, PT is an increasingly available 
alternative in cancer treatment as new centers are being built around the world.  In July 2005, 
there were 23 active proton centers and 3 centers using ions, and 43 000 and 4 500 patients 
were reported to have been treated with protons and ions, respectively[140]. By the end of 
2012, 42 facilities were reported to be in operation and the total number of patients treated 
was 107 792[141]. 
Protons, as opposed to photons, are charged particles with a defined mass, which leads to a 
different behavior in tissue. This difference is mainly in the physical properties of both 
modalities, while the biological effect can be seen as similar, due to the proximity of the 
clinical relative biological effectiveness of protons (RBE = 1.1) compared to photons[142]. 
The depth of maximum dose deposition of a proton beam can be made to coincide with the 
depth of the targeted disease. The treatment depth can be chosen arbitrarily by varying the 
proton beam energy. The main physical difference between radiotherapy with photons and 
protons can be described by the difference in the dose distribution as a function of depth in 
tissue produced by these two types of particles (Fig. 2). The presence of the Bragg peak in the 
proton beam dose profile is normally an advantage for proton beams compared to 
conventional photon beams because the region of maximum energy deposition can be 
  19 
positioned within the targeted volume, which results in a highly conformal high-dose region. 
Furthermore, with proton beams, the dose rapidly drops to zero beyond the depth of dose 
maximum, since the protons have then reached their maximum range in tissue. This also 
means that sensitive structures posterior to the target are protected from irradiation. In 
treatments with photons a considerable fraction will ionize beyond the target adding to total 
dose deposed both proximally and distally of the target. 
The techniques of delivery of protons have undergone considerable refinement since their 
introduction in medical applications. Up to recently, the only method was passive scattering. 
The beams extracted from the accelerator were mono-energetic and could not provide a 
uniform dose to a target of any significant size. Methods of modification by scattering foils, 
absorbers and filters, in order to broaden the Bragg peak, resulting in an extended spread out 
Bragg peak (SOBP) (Fig. 2), were used to obtain tumor coverage[143]. This posed a dose-
related problem, since the tissues inside the beam proximal to the tumor received higher 
radiation doses, and a logistical one, since a specific absorber had to be manufactured for 
each field, and for shifts in the patient’s anatomy during treatment. 
 
Figure 2. Central axis depth dose for photons and protons. The SOBP is illustrated in the 
multi energetic proton beam. 
A novel method of proton delivery, used at the Paul Scherrer Institute in Switzerland since 
over a decade, is the spot scanning proton beam technique. With this procedure, small sub 
volumes within the patient can be selected and irradiated one by one by adjusting the beam 
energy. The method is more selective compared to the previously used passive scattering 
delivery technique. With spot scanning, it is possible to reduce the unwanted radiation doses 
in healthy tissues surrounding the targeted disease even more than what is possible with 
previously used techniques[144, 145]. The dose reduction in healthy tissue, which is even 
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more accentuated when compared with standard photon RT, provides the potential for fewer 
side effects compared to what is observed after today’s treatments. 
Although patients have been treated with proton beams since half a century, the evidence of 
clinical benefits for PT remains very limited[146, 147]. This stresses the need of identifying 
potential groups of patients who might benefit from the different dose distribution pattern 
offered by PT compared to photons for future clinical trials. The dosimetric advantages of PT 
compared to photons have been described in a number of dosimetric studies, which compared 
doses to OARs and the risks of therapy-induced secondary cancer[148]. The majority of these 
reports have studied relatively small treatment volumes, i.e. intracranial lesions, prostate, and 
head-neck cancers. Tumors in these areas have long been considered as “traditional” proton 
targets. There are, however, limited data on the reduction of doses to OARs in larger 
treatment volumes in PT. Several simulation studies[149-152], mostly for intra-thoracic 
tumors, have explored the potential advantages of applying proton planning on large PTV 
volumes. However, among the latest reports, the scattering technique was used almost 
exclusively. An exception to this is the report by Radu et al[153], in which scanned proton 
beam planning for large volumes in rectal cancer resulted in decreased doses to the OARs 
compared to 3D conformal photon planning. In a recently published trial[154], the authors 
compared IMRT plans to 2-3 field plans in gastric cancer, and they reported lower doses to 
all OARs outside the PTV with PT. 
A large amount of skepticism was directed at the prospect of treating targets in the vicinity of 
bowels with protons, foremost with the active scanning technique, due to unpredictable bowel 
movements and bowel gas in particular. The radiation therapy planning is based on 
information about the electron density inside the patient. This density data is obtained from 
CT images, on which the position of the different tissues identified in relation to treatment 
beams.  The dose calculation algorithms incorporated in the treatment planning system (TPS) 
include a correction for tissue inhomogeneities, which is based on differences in electron 
density for different types of tissue. This correction is, however, static. Respiratory motion 
and changes in the organ composition and position, e.g. due to variations in intestinal gas 
filling, during the course of RT in gastric cancer can introduce large changes in tissue 
composition along the path of the beam. These anatomical inconsistencies may cause 
deviations in the dose distribution during the dose delivery due to variations in attenuation for 
photon beams and range for proton beams. For protons, there is in particular a high 
susceptibility for the dose prediction at the proximal and distal end of the intra-abdominal 
PTV in the beam. These uncertainties have been commented upon in published trials but have 
not been quantified[149, 153]. 
3.3 TARGET DEFINITION 
The target volume in gastric cancer consists of the gastric bed and remnant, the anastomoses, 
and lymph nodes (Table 2). In the case of large tumors (T3-T4), with invasion or close 
relationship with the abdominal wall, the abdominal wall is included. Recommendations for 
2D target construction were published following the Intergroup 0116 experience[155]. These 
  21 
recommendations are, however, inadequate in order to construct a 3D based CTV. A 3D 
approach, with higher degree of treatment conformity, resulting in lower doses to the 
OARs[156], requires in addition to strictly defined regions of interest, information from the 
preoperative gastroscopy and CT scan as well as the postoperative CT scan and renal 
scintigraphy. Furthermore, following the experience from the Japanese surgical patient 
material, the Maruyama Index (MI) was constructed, with the ability to predict the risk of 
involvement of any given lymph node station depending on the anatomical location of the 
primary tumor[157, 158]. This has lead to further invidualization of the CTV delineation. The 
inclusion of the lymph node stations into the CTV, based on the tumor location is presented 
in Table 3.  
Tumor	  location	  in	  the	  
stomach	  
Node	  station	  
number	   Lymph	  node	  stations	  
GE-­‐junction	  /	  Cardia	  /	  
proximal	  1/3	   stations	  1-­‐4;	  7;	  9-­‐11	  
para-­‐oesophageal,	  perigastric,	  
hepatogastro	  lig,	  celiac	  (left	  gastric	  artery,	  
celiac	  axis),	  splenic	  hilum,	  
suprapancreatic,	  porta	  hepatis,	  
pancreaticoduodenal	  	  
Corpus	  /	  Middle	  1/3	   stations	  3-­‐13	  
perigastric,	  suprapyloric,	  infrapyloric,	  
celiac	  (left	  gastric	  artery,	  common	  hepatic	  
artery	  and	  celiac	  axis),	  splenic	  hilum,	  
suprapancreatic,	  porta	  hepatis,	  
pancreaticoduodenal	  	  
Antrum	  /	  Distal	  1/3	   stations	  3-­‐9;	  11-­‐12	  
perigastric,	  suprapyloric,	  infrapyloric,	  
splenic	  artery,	  pancreaticoduodenal,	  porta	  
hepatis,	  celiac	  (left	  gastric	  artery,	  common	  
hepatic	  artery	  and	  celiac	  axis),	  
suprapancreatic	  	  
Table 3. Inclusion of lymph nodes in the CTV (based on CRITICS trial recommendations). 
The increasing conformity of dose coverage and the progressively shorter dose-fall-off 
obtained with new treatment techniques, such as IMRT and VMAT[138], stresses the need 
for standardized delineation in both trials and in clinical practice. There are also large inter 
physician variations in CTV contouring[159]. As a result, radiotherapeutic organizations 
proceeded to establish consensus guidelines to increase the grade of standardization in CTV 
delineation in the most common targets of RT[160, 161]. Recommendations for 3D CTV 
delineation in gastric cancer have been published by the Trans-Tasman Radiation Oncology 
Group (TROG)[162], a group in Boston[163], and also the CRITICS study group (CRITICS; 
clinicaltrials.gov NCT 00407186).  
3.4 NTCP AND RISK OF SECONDARY CANCER 
The adverse health effects of RT may be grouped into two general categories: the 
deterministic effects, i.e. harmful tissue reactions and the stochastic effects, i.e. cancer and 
inheritable effects[164]. The induction of deterministic tissue reactions is characterized by a 
threshold dose, above which the severity of the damage increases with dose. When the 
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threshold dose has been exceeded, early and late tissue reactions can be observed. The early 
tissue reactions appear days to weeks after exposure to radiation and are often of the 
inflammatory type, a result of the release of cellular factors and/or the treatment-induced cell 
death[164]. The late reactions appear months to years after exposure. The induction of 
stochastic effects is of the genetic type and due to the survival of mutated cells. Contrary to 
the deterministic effects, it does not have a threshold dose from which it starts to be observed. 
The evaluation of a treatment plan with regard to the risk of acute and late side effects is 
commonly done by assessing the 3D dose distribution, and reduced to dose-volume 
histograms (DVHs), which give information about the dose-volume frequency distribution 
for the target and the OARs. However, the DVH does not provide information about the 
expected biological response or the spatial information about which parts of the irradiated 
structures that received a dose deviating from the prescribed one.  Therefore, models of 
NTCP have been developed which can provide estimates of the biological response in the 
OARs to RT. The biological evaluation of the treatment plans for RT with either photon or 
proton beams can be calculated with the DVHs generated by the TPS[165]. This calculation 
model utilizes the tolerance levels reported in the Emami data[166].  
Fulfilling the delineation criteria stated in recommendations for CTV construction in gastric 
cancer, results in large and relatively complex PTVs (Fig. 3), in the direct vicinity of both 
kidneys, the liver, the bowel, and the heart. Furthermore, the dose to the bone marrow, in 
particular in combination with chemotherapy, and, in the case of tumors in the proximal 
section of the stomach, the dose to the lungs has to be considered. The applied total dose of 
45 Gy is below the spinal cord tolerance. Dose limiting organs for acute toxicity in gastric 
CRT are the stomach remnant, the bowel, and the bone marrow and for late toxicity the liver 
and kidneys[138].   
The radiation-induced secondary neoplasms, a stochastic late-term effect, can be the cost of a 
successful treatment of a primary malignancy[167, 168]. With the increasing numbers of 
cancer survivors[169], there is an increasing need to assess, by means of an accurate model, 
the risk of radiation-induced secondary neoplasms. There is furthermore, a need to compare 
the estimated risk of induced cancer after traditional photon beam therapy with the risk 
estimated for proton and heavier ions therapy[170]. 
Several models are used to estimate the risk of radiation-induced secondary tumors.  The 
International Commission on Radiological Protection (ICRP 60)[171] proposed a calculation 
scheme for the prediction of total mortality due to late effects. The United Nations Scientific 
Committee on the Effects of Atomic Radiation (UNSCEAR) has proposed a general equation 
that takes into account both the effects of radiation-induced DNA mutations and also the 
survival of the irradiated cells[172]. 
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Figure 3. Typical CTV and PTV in gastric cancer according to the CRITICS trial delineation 
atlas. 
Schneider et al[167] used the ICRP 60 calculation scheme to assess the total mortality of the 
patients due to late side effects after therapy with either photon or proton beams in Hodgkin’s 
disease. This risk assessment model uses the average organ dose and does not take the 
heterogeneity of the dose distributions in the different organs into account. The results from 
this study showed that the competition between the induction of the DNA mutations and cell 
survival should be included for risk estimations of radiation-induced secondary cancers and 
suggested a decrease in the cancer incidence after proton beam treatment compared to photon 
treatment. 
Dasu et al[173] performed a study of radiation-induced secondary cancer based on the 
equation proposed by UNSCEAR (1993). The authors modified this equation to take into 
account the treatment fractionation and also the non-uniform dose distributions to the 
irradiated organs. The results from the calculations of radiation-induced secondary risk with 
this modified equation were then compared with risk estimates obtained with two alternative 
methods. The results showed the importance of using the heterogeneous dose distribution in 
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4 AIMS OF THE STUDIES 
4.1 OVERALL AIMS 
The overall aim of the work presented in this thesis was to explore a new concept in 
chemotherapy, i.e. the sequential approach, and a new modality in radiotherapy, i.e. proton 
therapy, in the treatment of patients with gastric cancer. Quality of life in patients treated with 
chemotherapy, and delineation in  radiotherapy of gastric cancer, were also investigated. 
4.2 SPECIFIC AIMS 
The specific aims were 
 
- to evaluate the efficacy of sequential chemotherapy in patients with locally 
advanced and / or metastatic gastric cancer, with alternating irinotecan and 
docetaxel in combination with infusion 5-Fu, 
- to evaluate the effect of sequential chemotherapy on the quality of life of 
patients with locally advanced and / or metastatic gastric cancer, 
- to investigate the impact of inter observer variations on the delineation of CTV 
volumes in gastric cancer patients treated with perioperative CRT, 
- to evaluate the influence of proton therapy compared to modern photon 
radiotherapy  on the doses to organs at risk in gastric cancer patients treated 
with perioperative CRT, and 
-  to evaluate the impact of daily anatomical variations, i.e. intestinal gas filling, 
on the dose distribution of proton beam therapy. 
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5 MATERIALS AND METHODS 
5.1 PATIENTS 
All patients included in Paper I and II were recruited and treated in Swedish oncology centers 
participating in the GATAC trial. The participating centers and the numbers included by each 
site are listed in Table 4. All patient data were centrally collected and coded at the 
Department of Oncology, Uppsala University Hospital, Uppsala, Sweden. 
Site	   No.	  of	  patients	  
Uppsala	   13	  
Stockholm	   13	  
Karlstad	   1	  
Lund	   26	  
Eskilstuna	   1	  
Malmö	   6	  
Sundsvall	   5	  
Västerås	   5	  
Örebro	   3	  
Umeå	   6	  
Luleå	   2	  
Total	   81	  
Table 4. Patients included in Paper I and II by participating center. 
5.2 CT SCANS 
All CT scans utilized for the purpose of treatment simulation in Paper IV and V were 
obtained from patients included in the CRITICS trial at the Department of Radiotherapy at  
Karolinska University Hospital, Stockholm, Sweden. The CT scan used for CTV 
comparisons in Paper III was obtained at the Antoni van Leeuwenhoek Hospital, Amsterdam, 
the Netherlands.  
5.3 THE GATAC TRIAL 
5.3.1 Inclusion and exclusion criteria 
The study was a multicenter phase II trial aiming at randomizing 80 chemo-naïve patients, 
older than 18 years, with histologically verified metastatic or locally advanced 
adenocarcinoma of the stomach or cardia. Adjuvant therapy, including chemoradiotherapy 
after radical surgery, was allowed if finished more than 6 months before registration. Patients 
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with CNS-metastases or a history of other malignancies than gastric cancer, except curatively 
treated non-melanoma skin cancer or in situ carcinoma of the cervix or prior malignancies 
treated more than 5 years ago without recurrence, were not included.  
All patients had radiologically measurable lesions according to the RECIST-criteria, good 
performance status (WHO ≤2), and adequate hematological, renal, and liver functions. The 
latter was defined as hemoglobin (Hb) > 100 g/l, neutrophils (ANC) > 2.0 x 109/L, platelets > 
150 x 109/L, total bilirubin < 1.25 x upper normal limit (UNL), creatinine < 1.25 x UNL, 
ASAT and ALAT < 3 x UNL; in case of liver metastases, ASAT and ALAT < 5 x UNL. 
Patients with unresolved bowel obstruction, uncontrolled Crohn's disease or ulcerative colitis, 
or a current history of chronic diarrhea were excluded. All hematological and radiological 
assessments were done within 8 days and 3 weeks prior to randomization, respectively. The 
patients started treatment within 10 days from randomization. 
5.3.2 Chemotherapy scheme 
Patients were randomly assigned to start with either four courses of docetaxel 45 mg/m2 (arm 
T) or irinotecan 180 mg/m2 (arm C) with the simplified de Gramont regimen of 5-Fu/Lv 
(d1,2 q 2 w) (Fig. 4). After 8 weeks, i.e. 4 courses of treatment, patients switched to the other 
regimen, thus receiving an additional four courses of docetaxel (arm C) or irinotecan (arm T) 
with the same 5-Fu/Lv-schedule. The cross-over design of the GATAC trial is illustrated in 
Figure 4.  
 
Figure 4. The GATAC trial design. 
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dard error of 10%. Several responses were seen in both 
arms in the fi rst 9 patients. Taking into account antici-
pated ineligibility, inevaluability, and the second part 
of the study, the estimated number of patients to 
be enrolled per treatment arm was 40. OS and PFS were 
calculated from the date of randomization and assessed 
according to the Kaplan-Meier method. To test for sta-
tistical signifi cance, the t-test, χ2 test, and log-rank test 
were used (two-sided). A P value of <0.05 was consid-
ered statistically signifi cant.
Results
Eighty-one patients were randomized; 41 to arm T and 
40 to arm C. One patient was diagnosed with heart 
failure directly after randomization and did not start 
any therapy. Two patients, both in arm T, withdrew their 
consent before the start of treatment. Thus, a total of 78 
patients proceeded to treatment, i.e., 39 in each study 
arm. Patient characteristics are presented in Table 1. The 
two groups were well balanced for prognostic factors, 
save for gender. The number of patients treated with 
four and eight cycles, and reasons for dropout are shown 
in Fig. 2.
Seventy-one patients were evaluated for response 
after 8 weeks of treatment with either T or C. Of these, 
31 (44%) had a PR. There was no difference in objective 
response rates between the treatment arms (Table 2). 
After 16 weeks of treatment, a CR or PR as best 
response were seen in 2 out of 78 (3%) and 30 out of 
78 (39%) patients, respectively, again with no difference 
between treatment arms. Median PFS was 4.9 months 
for the entire patient population and 4.9 vs 5.0 months 
for arms C and T, respectively. Forty patients (51%) did 
not have progressive disease while on the study drug. 
The median PFS for this subgroup was 8.1 months 
(range, 4–29 months).
At the time of writing, 18 months after the last patient 
was included, 69 patients (88%) have died. The long-
Arm C Arm T 
4 cycles of irinotecan 180mg/m² as 
a 60 min. i.v. infusion with 5FU 
400mg/m2 i.v. bolus followed by   
2400 mg/m2 as a 44h i.v. infusion
with leucovorin. Cycle length: 2 
weeks.
4 cycles of docetaxel 45mg/m² as a 
30 min. i.v. infusion with 5FU 
400mg/m2 i.v. bolus followed by 
2400 mg/m2 as a 44h i.v. infusion 
with leucovorin. Cycle length: 2 
weeks.
4 cycles of docetaxel 45mg/m² as a 
30 min. i.v. infusion with 5FU 
400mg/m2 i.v. bolus followed by 
2400 mg/m2 as a 44h i.v. infusion 
with leucovorin. Cycle length: 2 
weeks.
4 cycles of irinotecan 180mg/m² as 
a 60 min. i.v. infusion with 5FU 
400mg/m2 i.v. bolus followed by 
2400 mg/m2 as a 44h i.v. infusion 




Stop or individual treatment 
Fig. 1. Gastric Cancer Taxotere vs. 
Campto trial (GATAC) study design. 
5FU, 5-Fluorouracil
Table 1. Characteristics of patients starting treatment
Patients Arm C Arm T
Number 39 39
Sex: female/male 13/26 5/34
Median age (range); years 63 (39–79) 64 (42–75)
Gastric surgery before study start (%) 16 (41) 17 (44)
Synchronous metastases (%) 22 (56) 18 (46)
Metachronous metastases (%) 12 (31) 16 (41)
Distant metastases (%) 34 (87) 34 (87)
Percentages of patients with involved sites 1 / 2 / 3 / >3 13/54/28/5 13/59/18/10
Percentages of patients with WHO status 0/1/2 44/44/1 60/39/18
Median hemoglobin level at randomization (range); g/l 120 (95–156) 125 (80–147)
Percent elevated alkaline phosphatase at randomization (range); µkat/l 56 (0.96–13.5) 41 (0.8–32)
µkat, microkatal
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Dose adaptations for toxicity were predefined in the study protocol. In case of Grade ≥ 2 
hematological or non-hematological toxicity at the day of infusion, the treatment was delayed 
until recovery (Grade<2). In case of febrile neutropenia or Grade 4 neutropenia, 
thrombocytopenia or leukopenia, the doses of both drugs were reduced by 20% for the next 
and subsequent courses of treatment. In cases of cumulative skin toxicity or peripheral 
neuropathy of Grade 3-4, only the docetaxel dose was reduced by 20%.  
Prior to treatment with docetaxel all patients received corticosteroids, most commonly 
dexamethasone. Prophylactic treatment with atropine was allowed before the administration 
irinotecan in order to prevent cholinergic symptoms.  
5.3.3 Evaluation of response – RECIST criteria 
Radiological evaluations were conducted by means of CT or MRI at base line and after four 
courses (8 weeks), i.e. at the switch of combinations, and after eight courses (16 weeks), i.e. 
at the conclusion of the 2nd drug combination. Patients must have received a minimum of 
four cycles of treatment with a minimum of one tumor assessment to be considered evaluable 
for response, unless “early progression” occurred in which case they were scanned earlier to 
be considered evaluable. 
Tumor response was evaluated with the efficacy criteria according to the EORTC Response 
Evaluation Criteria in Solid Tumors (RECIST)[174, 175]. All measurable lesions up to a 
maximum of five lesions per organ and ten lesions in total, representative of all involved 
organs, were identified as target lesions and recorded and measured at baseline. Target 
lesions were selected on the basis of their size, i.e. those with the longest diameter, and their 
suitability for accurate repeated measurements either imaging techniques or clinically. A sum 
of the longest diameter for all target lesions was calculated and reported as the baseline sum 
longest diameter. The baseline sum longest diameter was used as the reference by which to 
characterize the objective tumor response.  
All other lesions, or sites of disease, were identified as non-target lesions and were also  
recorded at baseline. Measurements of these lesions were not required, but the presence or 
absence of each was noted throughout the follow-up. 
The target lesions were evaluated according to following definitions: 
• Complete response (CR) = the disappearance of all target lesions. 
• Partial response (PR) = at least a 30% decrease in the sum of the longest 
diameter of target lesions, taking as reference the baseline sum longest 
diameter. 
• Progressive disease (PD) = at least a 20% increase in the sum of the longest 
diameter of target lesions, taking as reference the smallest sum of the longest 
diameter recorded since the treatment started or the appearance of one or more 
new lesions. 
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• Stable disease (SD) = Neither sufficient shrinkage to qualify for partial 
response nor sufficient increase to qualify for progressive disease, taking as 
reference the smallest sum longest diameter since the treatment started. 
The non-target lesions were further evaluated according to following definitions: 
• Complete response (CR) = the disappearance of all non-target lesions and 
normalization of tumor marker levels. 
• Stable disease (SD) = the persistence of one or more non-target lesions and/or 
the maintenance of tumor marker level above the normal limits. 
• Progressive disease (PD) = the appearance of one or more new lesions or 
unequivocal progression of existing non-target lesions. 
Evaluation of overall response was a combined assessment of the changes in both target and 
non-target lesions (Table 5). 
Target	  lesions	   Non-­‐target	  lesions	   New	  lesions	   Overall	  response	  
CR	   CR	   No	   CR	  
CR	   Incomplete	  response/SD	   No	   PR	  
PR	   Non-­‐PD	   No	   PR	  
SD	   Non-­‐PD	   No	   SD	  
PD	   Any	   Yes	  or	  no	   PD	  
Any	   PD	   Yes	  or	  no	   PD	  
Any	   Any	   Yes	   PD	  
Table 5. Evaluation of overall response according to RECIST. 
5.3.4 Assessment of adverse events 
An adverse event is defined as any symptom, sign, illness, or experience, which develops or 
worsens in severity during the course of the study. Intercurrent illnesses or injuries should be 
regarded as adverse events. Adverse events were recorded and graded according to National 
Cancer Institute Common toxicity Criteria (NCI-CTC) Version 2.0[176] before each new 
treatment course and up to 30 days after last study drug infusion. In case these criteria were 
not applicable, the event was defined as 1=mild, 2=moderate, 3=severe, 4=life-threatening. 
Grade 3 and 4 adverse events were defined as serious adverse events (SAE).  
An adverse event is classified as serious if it is: 
• Fatal 
• Life-threatening 
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• Requires or prolongs hospitalization 
• Results in a persistent or significant disability or incapability 
• A congenital anomaly or birth defect 
• An important medical defect 
5.3.5 Quality of life assessment 
Patient QoL was measured at baseline, before the fifth cycle and after the eight cycle of 
treatment. If the therapy was modified, the questionnaire was also filled in, thus, at the same 
points as the radiological evaluation. 
The evaluation tool used was the Swedish version of the European Organization for Research 
and Treatment of Cancer Quality of Life Questionnaire core 30 items (QLQ-C30) version 3. 
This tool consists of 30 questions, which cover general cancer specific aspects of the patient’s 
QoL. The first 28 questions are answered according to the following scale:  
1.  Not at all  
2.  A little  
3.  Significantly  
4.  Very much  
The last two questions addressing the global perception of the patients’ state of health and 
QoL, respectively, are answered on a seven point scale, with score of 1 representing a very 
poor and score of 7 an excellent status.  
Furthermore, the patients were asked to answer two additional questions after completing all 
treatment courses: 
1. Which of the two treatments did you find most effective? 
2. Which of the two treatments did you find most toxic? 
The latter added questions were answered before the patient received the results of the last 
radiological evaluation, by specifying the treatment given before and after the prescheduled 
switch.  The aim of these questions was to add an element of self-reported evaluation. 
The QLQ-C30 is composed of five functional scales, three symptom scales, a global health 
status / QoL scale, and six single items. The scales are addressed by more than one question 
in the questionnaire. All results are presented according to the EORTC QLQ-C30 Scoring 
Manual. This procedure results in all scales and single items in measures ranging from 0 to 
100, where the higher score represents better level of functioning in all functional scales and 
the global scale, but, contrary, in the symptom scales and the single items, where it represents 
a higher level of symptoms. 
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The scoring procedure if items I1, I2,…In are included in a score, is as follows: 
The Raw Score, an estimate of the average of the items that contribute to the scale  
 is first calculated:  
RawScore = RS = (I1 + I2 + … + In)/n 
Further the linear transformation to 0-100 is applied to obtain the score S: 
For functional scales:  
𝑆 = 1− (𝑅𝑆 − 1)𝑟𝑎𝑛𝑔𝑒   𝑥  100 
For symptom scales/items and global health/QoL: 𝑆 = (𝑅𝑆 − 1)/𝑟𝑎𝑛𝑔𝑒   𝑥  100 
Where, range is the difference between the maximum possible value of RS and the minimum 
possible value. The QLQ-C30 has been designed so that all items in any scale take the same 
range of values. Therefore, the range of RS equals the range of the item values. Most items 
are scored 1 to 4, giving range = 3. The exceptions are the items contributing to the global 
health status / QoL, which are 7-point questions with range = 6, and the initial yes/no items 
on the earlier versions of the QLQ-C30 which have range = 1. 
In order to evaluate whether there was a positive or negative development of the patients’ 
perception of their QoL we looked at the direction of the change (viz. positive or negative), 
and at the change in mean scores for all 15 scales in the questionnaire.  A clinically 
significant shift was defined as a difference of over 10 points on a 100-point scale, thus 
corresponding to a moderate or large change in accordance to EORTC 
recommendations[177]. 
5.4 RADIOTHERAPY 
Target delineation in Paper IV and V was performed in accordance with the CRITICS 
protocol and its attached delineation atlas.  All CTVs included the gastric bed/gastric 
remnant, the anastomoses, and lymph node stations in accordance with the Maruyama data. 
The liver, both kidneys, the heart, the spinal cord, bone marrow, and the bowel outside the 
PTV were delineated as OARs. The latter included both the large and small bowel from the 
diaphragm to 1.5 cm below the PTV. In female patients, the breast tissue, and in all patients 
the lungs, esophagus, bone, and skin were delineated for the purpose of calculation of 
secondary cancer risk. A PTV margin of 1 cm was added to the CTV. All delineations were 
reviewed by the weekly gastrointestinal target discussion panel at the Department of 
Radiotherapy, Karolinska Hospital, consisting of oncologists experienced in target definition 
for gastrointestinal malignancies. 
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Planning for both modalities was performed in Eclipse (Varian Medical Systems, Palo Alto, 
CA, USA). For the photon plans, a Varian accelerator was used and for the proton plans an 
IBA machine. All photon plans were generated with volume modulated arc therapy (VMAT) 
technique, using two full arcs and an energy of 6 MV.  
5.4.1 Photon planning 
The photon treatment planning in Paper IV and V was performed with Rapid Arc, the Varian 
approach of VMAT. In VMAT, the dose is delivered during continuous gantry rotation and 
collimator motion[178]. The dose distribution can be optimized based on dose-volume 
objectives. The MLC openings and monitor units (MU) weights are optimization parameters. 
With VMAT the gantry rotation, MLC motion, and dose rate modulation are coordinated 
simultaneously. 
The optimization process in Rapid Arc is based on the Progressive Resolution Optimizer 
(PRO) algorithm[179], in which the entire gantry rotation is described as a sequence of 177 
control points equally spaced by roughly 2o. For each control point, the gantry angle, dose 
rate, and MLC leaves opening shapes are specified. The optimization process proceeds 
through five multi-resolution levels. The first resolution level has 10 control points and it has 
an initial distribution of the MLC shapes; the dose rate and gantry speed are then set to their 
maximum allowed values[180]. During each multi-resolution level, the MLC shapes, dose 
rate, and gantry speed are simultaneously optimized for a fixed number of iterations. The 
process is repeated by doubling the number of control points at each level until the final 
number of 177 (360o arc) control points is reached. The Varian Eclipse TPS for photon beam 
therapy uses the Analytical Anisotropic Algorithm (AAA) as dose calculation model. 
5.4.2 Proton planning 
Several attempts were made to find a field configuration that provided optimal robustness for 
the proton plans. In esophageal cancers and retroperitoneal targets, a posterior approach with 
two oblique fields is most commonly used. For centrally located abdominal tumors, i.e. 
pancreas and the stomach, variations of lateral, posterior, and anterior field settings have been 
applied. The CTV/PTV in patients with gastric cancer is encompassed by structures with 
variable air content, i.e. lungs/diaphragm, gastric remnant, and the large and small bowel, 
which resulted in uncertainties regardless of the chosen field configuration. We therefore 
decided on the optimal field setup of proton planning, which provided the best target 
coverage and OAR sparing for these large and complex target volumes.  
Proton plans were based on two beams, one left lateral at 90 degrees and one oblique frontal 
at 345 degrees (Figure 5). Both beams were optimized with single field uniform dose (SFUD) 
in order to increase robustness. The proton beam was of the spot scanning type, with an 
energy range of 70-235 MeV. 
Proton planning was performed using beam data from the University of Pennsylvania proton 
machine (IBA proton therapy system), since the beam data from the Swedish Skandion Clinic 
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were not yet available. Since these machines are quite similar and from the same 
manufacturer, it was considered to be an acceptable approach for estimating the future 
treatment possibilities at the new Swedish center. 
The relative biologic effectiveness (RBE) of 1.1 is widely used for protons[181]. As this fact 
has an implication for prescription rather than for comparison, physical doses were compared 
in Papers IV and V. 
 
Figure 5. Dose distribution and beam arrangement. For photon therapy (left side), and for 
proton therapy (right side). 
5.4.3 NTCP calculation 
A biological evaluation of the dual treatment plans was performed by calculation of normal 
tissue complication probability (NTCP). To compute the NTCP, the Lyman-Kutcher-Burman 
(LKB) model was implemented in a computer program (MatLab R2012a)[182]. This model 
is based on a four-parameter equation (Eq. 1), and makes use of the Emami data[166, 183]. 
𝑁𝑇𝐶𝑃 = !!! 𝑒!!!! 𝑑𝑡!!!                                                            (Eq. 1) 
where  𝑡 = !!"#!!"!"(!)!∙!"!"(!)                                                                 (Eq. 2) 
and 𝑇𝐷!" 𝑣 = 𝑇𝐷!"(1) ∙ 𝑣!!                                                       (Eq. 3) 𝑇𝐷!" 𝑣  is the tolerance dose which leads to 50% complication probability for uniform 
irradiation of the fractional volume 𝑣 of the organ at risk (OAR); when the whole organ is 
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irradiated 𝑣 = 1 and the tolerance dose is 𝑇𝐷!"(1). The parameters 𝑛 and 𝑚 are, 
respectively, the volume factor, which describes the volume dependence of the NTCP, and 
the slope of the NTCP vs. dose curve. 
The NTCP equation is applicable under conditions of homogeneous irradiation of the OAR. 
In order to accommodate the clinical data, which are for inhomogeneous irradiation, the 
current non-uniform DVHs have to be transformed to uniform. For this purpose, the effective 
volume method[165]  was used. Additionally the linear quadratic (LQ) model was used in 
order to correct the physical DVHs for fractionation effects by conversion of the delivered 
total dose D to the 2 Gy equivalent dose per fraction through the equation (Eq. 4)[184]. 
𝐿𝑄𝐸𝐷! = 𝐷 ! !!!! !!!                                                                 (Eq. 4) 
Where 𝐿𝑄𝐸𝐷! is the linear-quadratic equivalent dose for 2 Gy per fraction. The data used for 
calculation are shown in Table 6. Due to the high inhomogeneity in dose distribution in the 
heart and the spinal cord, the NTCP was not calculated for these organs, as the reliability of 
the calculation model would be questionable. 
Organ	   α/β	   TD50	  (Gy)	   N	   m	  
Kidney	   3	   28	   0.7	   0.1	  
Liver	   2	   40	   0.32	   0.15	  
Bowel	   3.9	   55	   0.15	   0.16	  
 
Table 6. Variables used for calculation of NTCP. 
5.4.4 Estimates of risk of treatment induced neoplasms 
Presently, there is no single “gold standard” for the estimation of risk of treatment-induced 
malignancies and there is, furthermore, an ongoing debate as to the shape of the dose-
response curve for radiation-induced tumors. It has been discussed in several publications that 
the traditional linear-quadratic model is insufficient in describing this relationship[173]. 
Clinical investigations have shown that the dose response relationship for cancer induction 
following radiotherapy has either of two main characteristics: an increase of the risk with 
dose to a maximum effect followed by a decrease or an increase followed by a leveling-off of 
the risk[173, 185, 186]. 
The induction of secondary cancer following external beam radiotherapy can be estimated 
using a model by Dasu, which takes into account both the heterogeneity of the dose 
distribution in the irradiated organs and the fractionation schedule of the radiotherapy 
delivery[173]. This model, which was applied in Paper IV, is based on the LQ model and 
makes use of a general equation (Eq. 5) proposed by UNSCEAR[172]. It takes into 
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consideration both the probability for therapy-induced DNA mutations and the probability for 
survival of the irradiated cells. 
The risk model adopted for calculating the risk of secondary cancer is the following (Eq. 5): 𝐸𝑓𝑓𝑒𝑐𝑡(𝐷) = 𝑎!𝐷 + !!!!! ∙ 𝑒𝑥𝑝 − 𝑎!𝐷 + !!!!!                                          (Eq. 5) 
 
Where, 𝑎! and 𝑏! are the parameters describing the induction of DNA mutations and 𝑎! and 𝑏! are the radiobiological parameters of the LQ model for cell survival, 𝑛 is the number of 
fractions of the treatment protocol and D is the prescribed total dose.   
The risk for induction of secondary cancer is then estimated by the use of Eq. 6 which was 
proposed by Dasu [173]. The risk for each OAR is calculated by means of this competition 
model in all the bins of a DVH and the total risk per organ is finally obtained by summation: 
 𝑇𝑜𝑡𝑎𝑙  𝑒𝑓𝑓𝑒𝑐𝑡 = !!! ∙!""#$% !!!!!                                                          (Eq. 6) 
 
For the estimation of the risk of radiation-induced secondary cancers, Dasu made certain 
assumptions. In Eq. 5 it was assumed that both the probabilities for induction of DNA 
mutation and the probability of cell survival have the same α/𝛽 parameter. Furthermore, for 
low doses, the quadratic term for induction of DNA mutations is negligible and the same 
assumption of low doses was made for calculations in Paper IV. The parameter 𝑎! is the 
linear coefficient, which describes the relative probability of cancer risk in different organs 
for the nominal world population and is listed in the ICRP 60[171]. For every patient 
included in this study, the risk of developing secondary malignancies was determined for the 
most important OARs for the two treatment modalities. 
5.5 STATISTICAL ANALYSIS 
All statistical analyses were performed using the IBM SPSS computer program (version 
18.0). 
In the GATAC trial (Papers I and II), the primary aims were to explore the efficacy, i.e. 
objective response rate. Secondary aims included toxicity, overall and progression-free 
survivals of the planned sequential administration of the two drug combinations. If no 
complete or partial response (CR+PR) were seen in the nine first patients in each treatment 
arm, indicating that the response rate would be less than 30%, the trial would be closed for 
that treatment arm (Gehan’s Method Phase II Trials, Step 1). If three or more responses were 
seen among the first fourteen cases an additional nine patients were to be added (Gehan’s 
Method Phase II Trials, Step 2). It would then be possible to estimate the response rate with a 
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standard error of 10%. Several responses were seen in both arms in the first nine patients. 
Taking in account anticipated ineligibility, inevaluability, and the second part of the study, 
the estimated number of patients to be enrolled per treatment arm was forty. OS and PFS 
were calculated from the date of randomization and presented according to the Kaplan-Meier 
method. To test for statistical significance in Paper I, the t-test, x2-test, and log-rank test were 
used. A p-value of <0.05 was considered statistically significant. In Paper II, the Fisher’s 
Exact Test was used for statistical comparison between the treatment arms. A p-value of 
<0.05 (Exact Sign. (two-sided)) was considered statistically significant. The Mann-Whitney 
U-test was used to analyze the correlation between radiological response and the shift in 
global QoL scores. The statistical analysis in Paper II was performed in collaboration with the 
Unit of Medical Statistics at the Karolinska Institute (LIME/MedStat). 
In Papers IV and V, the differences between treatment modalities (Paper IV) and the dose to 
target organs and OARs changes  (Paper V) were analyzed with pairwise Wilcoxon signed-
rank test. This test is performed when subjects are tested under two different circumstances. 
The level of statistical significance was set at p ≤ 0.05.  
5.6 ETHICAL CONSIDERATIONS 
The GATAC study protocol (Papers I and II) was approved by the Ethics Committee at the 
University of Uppsala and by Regional Ethics Committees of the participating hospitals. All 
patients were required to give written informed consent. 
Patients included in Papers IV and V participated in the CRITICS study, which was approved 
by the Ethics Committee of the Stockholm Region. The patients were informed about the 
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6 RESULTS AND DISCUSSION 
6.1 PAPER I - SEQUENTIAL CHEMOTHERAPY IN ADVANCED GASTRIC 
CANCER 
This is the first randomized comparison of prescheduled sequential combination treatment in 
gastric cancer. In addition, it allows a head-to-head comparison of early response rates and 
toxicity of the two drugs docetaxel (arm T) and irinotecan (arm C), combined with 5-Fu. In 
this trial, the primary aim was to study the efficacy, i.e. objective response rate, and 
secondary aims included the toxicity profile, overall survival, and progression-free survival 
(PFS) of the planned sequential administration of the two drug combinations. 
Of the 81 patients randomized, 78 proceeded to treatment, i.e. 39 in each arm (Figure 4). 
Patient characteristics were very similar in both treatment arms, with the exception of gender, 
i.e. 33% females in arm C compared to 13% in arm T. The most common reasons for dropout 
during the duration of the trial were either death (six patients) or tumor progression (six 
patients). None of the deaths during the trial was attributed to toxicity. 
The response rates in all patients were 44% and 43% after 8 and 16 weeks of treatment, 
respectively. At the end of the treatment, two patients had a complete response. Median PFS 
was 4.9 months for the entire patient population and 4.9 vs. 5.0 months for arms C and T, 
respectively. Forty patients (51%) did not have progressive disease while on study drug. The 
median PFS for this subgroup was 8.1 months (range 4 – 29). No difference in objective 
response rates between treatment arms was seen. Median follow-up time was 11 months. 
Median OS was 11.5 and 10.6 months in arms T and C, respectively, a statistically non-
significant difference (p=0.33). Due to the uneven distribution of gender in the treatment 
arms, we calculated the median OS according to gender. We found no difference in survival 
between males and females. A small group of ten long-term survivors was identified, which 
was evenly spread between the treatment arms. The survival times for these patients varied 
between 17 and 37 months. Five of these patients (6% of the total patient population) 
underwent surgery with curative intent after completion of chemotherapy; four had a 
gastrectomy and one a deperitonealisation. Notably, four of these patients had no distant 
metastases at inclusion. One patient died 37 months after randomization and 21 months after 
surgery in recurrent gastric cancer.  
No significant differences in toxicity were found between the two treatment arms. One 
hundred and twenty-eight Grade 3 and nine Grade 4 toxicities were registered in both arms 
combined. One patient underwent acute surgery due to intestinal obstruction. The most 
common adverse event was hematological toxicity (20%).  Anorexia, fatigue, or infections 
were reported in 15% of patients, respectively. It can be argued whether dysphagia, which 
appeared in eight patients, was related to the treatment or to the tumor itself or to previous 
surgery. The vast majority of SAEs occurred during the first four treatment cycles. This could 
be partly explained by the fact that most events (58%) occurred in patients who did not 
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complete the whole treatment and partly by dose reductions when toxicity was observed 
during the first treatment cycles. In almost half of the patients (43% of those having 
completed all 8 cycles), no Grade 3 or 4 SAEs were observed.  
In conclusion, no differences favoring either arm T or C were found with respect to response 
rates or toxicity after 16 weeks of therapy. Furthermore, no differences in survival outcome 
could be detected whether treatment was initiated with either irinotecan or docetaxel. This 
shows that both combinations are effective in the treatment of locally advanced and / or 
metastatic gastric cancer and that they can be safely administered in random order. 
The main interest of our results is, however, that an objective response rate of 41% and a 
median OS of 11 months were reached in a multicenter trial and a population consisting of 
87% patients with distant metastatic disease. These results are at least comparable to recently 
reported efficacy of combinations including cisplatin or combinations of three cytostatic 
agents. 
In general, combinations of irinotecan or docetaxel with 5-Fu have been better tolerated than 
combinations of cisplatin and 5-Fu, but have resulted in more gastrointestinal toxicity[95]. 
Neutropenia is a major problem for combinations of either irinotecan or docetaxel with 
cisplatin[95, 101], and is especially problematic for the TCF (docetaxel, cisplatin, 5-Fu) 
combination. The relatively low toxicity seen in this trial is probably a result of “switching” 
the drug combination after 4 cycles and thus reducing the typical toxicity of each of the study 
drugs, i.e. hematological for docetaxel and gastrointestinal for irinotecan. 
6.2 PAPER II - QOL IN PALLIATIVE GASTRIC CANCER TREATMENT 
There are limited data reporting on the effect of palliative chemotherapy on QoL in patients 
with gastric cancer, and none in a sequential setting. This is, however, a crucial parameter 
that has to be considered in the process of clinical decision making, as to which or whether 
palliative chemotherapy should be recommended for these patients. Therefore, the component 
of QoL-assessment was included in the GATAC trial. The primary objective was to explore 
whether there was any difference in QoL depending on which regimen was given first. 
Secondary aims included the evaluation of changes in the QoL scores during treatment vs. 
baseline and an evaluation of whether they were correlated to or independent of the 
radiological response of the tumor. 
A total of 191 completed QoL questionnaires were collected. The compliance rate in 
answering questionnaires was 96% at baseline, 85% after 4 courses, and 64% after 8 courses 
of treatment, which is comparable to other trials assessing QoL. In only nine cases the 
missing questionnaires were not rendered by disease progression, toxicity, or death. Forty-
seven patients completed all three assessments and in those cases the changes in QoL could 
be evaluated for both treatments. Furthermore, 110 treatment periods of eight weeks could be 
assessed separately, with completed questionnaire at the start and end of the period, in order 
to evaluate the dependency of QoL on radiological response.  
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No statistically significant differences were detected between the two treatment arms at 
baseline or during the 16 weeks of treatment in all scales of QoL (p values ranging from 
p=0.076 to p=0.946), with the exception of insomnia. Patients in arm T had less often a 
negative change between baseline and the evaluation at 8 weeks than in arm C (8% vs. 32% 
of patients reporting increased insomnia, p=0.025). 
The majority (55%) of all patients reported a clinically moderate or large improvement (>10 
points) in global health status/QoL during the duration of the treatment. Only 19% reported a 
moderate or large deterioration. There was no statistically significant change (p= 0.797) 
during treatment in the patients’ scoring of their global health status/QoL. There was, 
however, a trend for rising mean and median scores during the treatment period compared to 
baseline for both treatment arms. This trend was present in other functional scales, with the 
exception of cognitive and social functioning. Similarly, the scores for most single items, 
with the exception of dyspnea and diarrhea, showed a trend towards decrease, thus less 
pronounced symptoms. Both fatigue and loss of appetite were the highest scored symptoms at 
baseline, and fatigue remained as the highest scored after completing the treatment. 
In order to connect the radiological evaluation to the QoL change, which was reported to be 
dependent of one another in several previous trials in gastric cancer, patients were divided 
into those who had a radiological response (CR or PR) and those who did not (SD or PD). 
We then compared the proportion of patients reporting a clinically significant positive, a 
negative or no shift in the global QoL scores during the entire treatment and during the first 
and second treatment period. During the first treatment period (first 8 weeks) there was a 
trend for improved scores for the radiologically responding patients, however, the difference 
was statistically not significant (p=0.168). During the second treatment period (last 8 weeks), 
however, there was a statistically significant difference (p=0.007), i.e. 82% of responding 
patients reported a positive change or unchanged global QoL score compared to 50% among 
those with no response. No significant correlation for the other scales or single items was 
found between the change in scores and radiological response except for nausea and 
vomiting. In the non-responding group, 34% experienced aggravated symptoms compared to 
22% among responders (p=0.035). 
Although the population consisted of 87% of patients with distant metastatic disease, many of 
these in several sites, the patient population reported good QoL and relatively few symptoms 
at baseline. Therefore, the fact that good QoL can be sustained during sequential treatment 
emphasizes the role of palliative cytotoxic treatment in this patient group. It also stresses the 
importance of choosing an effective palliative treatment with minimal toxicity. As in most 
trials addressing QoL, some caution should be taken in interpretation of the results, due to 
potential skewness of data as a result of missing evaluations. These missing data may 
represent deterioration of patients’ QoL. Methods, such as reporting by proxy or self-reported 
QoL, are being established in clinical studies, and might increase the validity and 
generalizability of QoL-data. This uncertainty makes it important to establish reliable early 
predictors of treatment response. 
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6.3 PAPER III - ATLAS BASED CTV DELINEATION IN GASTRIC CANCER 
The protocol for the CRITICS trial included a CT-based atlas with guidelines for CTV 
delineation in proximal, middle, and distal gastric cancer. A consensus discussion among the 
responsible oncologists and two experienced radiologists, specializing in abdominal 
diagnostics, verified the anatomical accuracy of the atlas. Furthermore, instructions for the 
PTV construction were defined in the protocol. In this study, after implementation of a 
delineation protocol, inter physician variability was tested by comparing target volume 
delineations and treatment plans from 10 different institutes on 1 example case. The primary 
aim of this study was to quantify the variations in delineated CTV and PTV volumes. The 
secondary aim was to evaluate the effect of the registered variation on PTV coverage and 
doses to the OARs. 
Six centers in the Netherlands and four in Sweden participated in this trial. All centers were 
provided with the same clinical information about the patient, including the pre- and 
postoperative CT-scans in addition to the planning scan.  According to the guidelines in the 
atlas, the CTV in the study patient had to consist of the tumor bed with the gastric remnant, 
the gastrojejunal anastomosis and duodenal stump, and perigastric, suprapyloric, infrapyloric, 
celiac, splenic hilum, suprapancreatic, porta hepatis, and pancreaticoduodenal lymph nodes. 
In all centers, the radiation oncologist with most experience in upper abdominal tumors, 
delineated the CTV. However, with the exception of NKI, the participating centers had no or 
little experience in irradiation of gastric cancer. Furthermore, all centers were asked to 
provide clinically acceptable treatment plans in accordance with the study protocol, and based 
on their own delineations. 
The ten CTV and PTV delineations were compared by means of the volume and overlap 
between institutions. Subsequently, a 3D median PTV was constructed out of the delineated 
PTVs, defined as the volume included by at least 50% of the observers. Target coverage was 
compared by the application of the planned dose to the median PTV. Furthermore, the doses 
to OARs were analyzed for the liver and both kidneys. For the liver the mean dose was 
calculated, whereas for the kidneys the relative volume receiving more than 20 Gy was 
calculated for each separate kidney.  
Large inter observer variation was found in the analysis of CTV and PTV volumes. The CTV 
volume ranged between 240 cm3 and 821 cm3 (average = 392, 1SD = 176). On average, the 
CTV overlap between institutions was 72%, whereas for the PTV the average overlap was 
78%.  
The PTV volume, ranged between 634 cm3 and 1677 cm3 (average = 915, 1SD = 312). The 
resulting median PTV had a volume of 890 cm3. The minimum observer variation was found 
at the border of the liver and the left kidney (1–3 mm SD). Maximum observer variation was 
found at the caudal part of the target volume, ranging up to 19 mm SD. This could be 
attributed to the difficulty in defining the section of the diaphragm and the extent of 
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periesophageal nodes included in the CTV. For the remainder of the PTV, observer variation 
was on average 7 mm SD, ranging between the minimum and maximum.  
All participating centers met the preset requirements of PTV coverage in their treatment 
plans, which resulted in the average V95 of 99.5% (range, 98.4–100%). All institutes also 
succeeded in minimizing the dose to the OARs. The mean liver dose, which had to be <30 
Gy, was on average 24.3 Gy (range, 20.5–27.3 Gy). All institutes sacrificed the left kidney 
and spared the right one for good target coverage, with an average V20 of 94.2% (range, 
65.2–100.0%). The V20 for the right kidney was on average 12.0% (range, 1.6–32.4 %), 
which was adequately below the constraint of 33%. 
Despite the use of the delineation atlas and the contouring workshop, substantial inter 
physician variation was found in this trial. Although differences in delineation between 
institutes were in the order of centimeters, because of the size of the total target volume, the 
effect on coverage of the median PTV was relatively small (approximately 10%). The impact 
of these variations may, however, become larger as more conformal treatment techniques, 
such as IMRT and VMAT, are more commonly used. Furthermore, adjuvant CRT in gastric 
cancer in Europe is today not considered as standard of care and, thus, the relative lack of 
experience in constructing a complex target in this region may have influenced the large inter 
physician variation in this trial. 
6.4 PAPER IV - PROTON TREATMENT, DOSES TO OARS AND SECONDARY 
CANCER IN GASTRIC CANCER 
The clinical benefits of proton therapy (PT) remain uncertain. There is a need to identify 
potential groups of patients who may benefit from the different dose distribution patterns 
offered by PT compared to photons. The normal tissue sparing effect of protons can 
potentially be greater in large target volumes, such as in gastric cancer, than in the classical 
proton targets. Furthermore, PT may also lower the risk of therapy-induced secondary 
neoplasms, which is of importance with increasing survival rates and life expectancy in 
cancer patients. The aim of this study was to explore, by means of dosimetric comparison, the 
potential sparing effect on OARs and the risk of therapy-induced secondary tumors of 
scanned proton beam planning in patients with gastric cancer undergoing postoperative RT 
compared to photons. 
Nine consecutive patients with gastric cancer, included in the CRITICS trial and referred to 
the Department of Radiation Oncology at the Karolinska University Hospital for 
postoperative CRT between November 2008 and December 2013 were asked to participate in 
this study. All patients were previously treated with neoadjuvant chemotherapy followed by 
R0 total (n=1) or partial gastrectomy (n=8). One patient was excluded due to a prior 
splenectomy, which resulted in a large disarrangement of the upper abdominal anatomy.  
The prescribed dose was 45 Gy in 1.8 Gy fractions. For each of the eight patients one VMAT 
and one scanned pencil beam (PBS) proton plan was generated. The optimization was 
performed with the aim of achieving a minimal and maximal dose in the PTV of 95% and 
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107%, respectively, in all cases. The mean liver dose did not exceed 30 Gy and the allowed 
maximal dose in the spinal cord was below 45 Gy. In every case, an effort was made to spare 
one kidney as much as possible, and in no cases did 2/3 of one kidney receive more than a 
maximum of 40% of the prescribed dose. The VMAT plan was the actual clinical plan.  
In order to compare plans with different modalities, cumulative dose-volume histograms were 
calculated for the OARs. For the kidneys, the level of 18 Gy was chosen due to indications of 
a threshold value for RT-induced renal injury, with a risk of 5% and 50% for whole kidney 
irradiation with 18 Gy and 28 Gy, respectively[187, 188]. For the liver, the mean organ dose 
was registered, which is a predictor of the risk of developing radiation-induced liver disease 
(RILD), as well as the volumes receiving 10 Gy (V10) and 30 Gy (V30)[189]. Organ 
volumes of the bowel outside the PTV receiving 30 Gy and 40 Gy and the mean dose were 
registered. The V25 Gy in the heart was evaluated. The maximum dose to the spinal cord was 
obtained for each plan. Rarely, the CTV encompassed the lower paraesophageal lymph 
nodes, thus, very limited dose to the base of the lung was found. Thus, the lung doses were 
not considered clinically significant.  
Patient age ranged between 42 and 71 years (median 65.5 years). The CTVs and PTVs varied 
from 576 to 1032 cm3 (median 767 cm3) and from 1146 to 1836 cm3 (median 1505 cm3), 
respectively. All sixteen plans met the preset constraints. The coverage of the PTV and the 
CTV was compared for all pairs of plans and ranged from 97.5% to 99.7% for the PTV. 
There was no statistical difference in coverage between the two groups (p=0.498). 
Doses to OARs and NTCP were reduced in all organs except the bowel outside the PTV and 
the heart in the proton plans compared with VMAT plans. Protons offered significantly lower 
doses to the left kidney, liver, and spinal cord (p=0.012). Due to the used planning technique, 
no gain was seen in the dose to the bowel outside the PTV and the heart. The proton plans 
resulted in statistically lower risks for all types and malignant secondary neoplasms compared 
to photon plans (p=0.012 and p=0.011, respectively). 
6.5 PAPER V - GAS VARIATIONS IN THE ABDOMEN AND SCANNED 
PROTON THERAPY 
In patients with gastric cancer, proton therapy (PT) can reduce doses to OARs due to the 
defined range in tissues and advantages in depth dose distribution. In the majority of trials in 
PT in the abdomen, proton plans were developed with the passive scattering technique. A 
large amount of skepticism was directed at the prospect of treating targets in the vicinity of 
bowels with protons, especially with the active scanning technique, due to unpredictable 
bowel movements and bowel gas in particular. Dose distribution in PT has a high 
susceptibility to variations in tissue homogeneity, in particular at the proximal and distal end 
of the intraabdominal PTV, of the beam. These uncertainties have been commented upon in 
published trials but they have not been quantified. The aim of our study was to quantify the 
influence of large variations in gastrointestinal gas filling on dose distribution in large upper 
abdominal targets when using the scanned proton radiation technique. 
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Eight patients, participating in the CRITICS trial, were included. For each patient, a PBS 
proton and VMAT photon plan was made in order to deliver 45 Gy in 25 fractions with 
comparable PTV coverage. For each patient, both plans were created on the original planning 
CT scan. When the plans were considered acceptable they were applied on two altered 
planning CT scans representing variations of the gas filling in the abdominal organs, i.e. the 
bowels and the gastric remnant. The dose distributions for both protons and photons from the 
original plan were recalculated on the two altered CT scans. 
In the first altered scan, we simulated a situation in which no gas would be present in the 
treatment situation. All gas in the intestines and in the gastric remnant at the axial level of the 
PTV was delineated and the volume enclosed was set to replicate water, by setting the 
Hounsfield value (HU) to 0. 
In the second CT scan, we simulated a situation in which more gas would be present in the 
abdomen. The previously delineated bowel gas was expanded with 1 cm in all directions. 
Areas expanding into the OARs and the thoracic wall were subtracted. The latter procedure 
was done in order to hinder the interchange of bony structures, i.e. ribs with air. The entire 
enclosed volume was then defined as gas by setting the HU value to -1000.   
The mean gas volume on the planning CT scan and thus the volume of gas changed to water 
equivalent on the first altered CT was 370 cm3 (range 226-605 cm3) and the mean gas volume 
after expansion in the second altered CT scan was 743 cm3 (range 394-1051 cm3). 
The substitution of air with water equivalent as well as the addition of extra air had only 
minor impact on the PTV/CTV coverage in VMAT planning. The change was larger when 
air was substituted with water, with PTV coverage dropping from 99% to 93% and from 99% 
to 94% in two patients.  
However, in the proton plans, the registered shifts in PTV/CTV coverage were larger and 
clinically probably more significant. Due to the field arrangement and proton plan 
susceptibility to variation in tissue homogeneity, there was a shift of the high dose areas 
towards the ventral abdomen when air was substituted with water equivalent resulting in 
under dosage of the dorsal part of the PTV and higher dose in the bowel outside the PTV. 
Contrary, when extra air equivalent was added the shift of high dose areas was towards the 
dorsal/right abdomen resulting in under dosage of the ventral PTV and higher doses to the 
right kidney and liver. These variations were dependent on the initial volume of the 
gastrointestinal gas and its location in relation to the proton beams. The median PTV 
coverage with 95% of the prescribed dose dropped from 99% (range 98-99%) in the original 
plan to 91% (range 78-97%) when air was substituted with water equivalent and to 86% 
(range 58-98%) when the extra air equivalent was added. Similarly, the median CTV 
coverage with 95% of the prescribed dose changed from 100% to 97% (range 80-100%) and 
91% (range 54-100%), respectively. However, in all cases, the sparing effect of protons was 
sustained or the dose to the OARs did not significantly exceed the dose delivered with the 
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corresponding photon VMAT-plans. The gas variations never resulted in doses exceeding the 
preset constraints for the OARs. 
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7 CONCLUSIONS AND FUTURE PERSPECTIVES 
7.1 PAPER I 
The results of the GATAC trial indicate that sequential administration of the two presented 
combinations is feasible and effective with similar median OS as for the commonly used, 
more toxic, ECF/EOX/TCF-combinations, which suggests that comparable efficacy can be 
obtained with less toxic regimens if given in a sequential fashion. Another observation is that 
in a small group of patients, with locally advanced tumors, at diagnosis considered non-
resectable, tumor reduction was obtained to such a degree, that the patient could be 
reconsidered for surgery with a potentially curative intent. Furthermore, despite the generally 
poor prognosis of patients with metastatic gastric cancer, a subgroup of patients had a 
considerable gain in the form of durable PFS and overall survival. Our results are 
encouraging, meaning that sequential chemotherapy is a strategy well worth further 
investigation in the treatment of gastric cancer and other GI-malignancies. In this context, 
sequential chemotherapy, with comparable overall survival and low toxicity in comparison to 
triple drug combinations, is an attractive alternative. Furthermore, the results of the GATAC 
trial in combination with results of similar trials in other tumor sites, foremost in adjuvant 
breast cancer treatment, stress the question whether sequential treatment should be further 
explored as an alternative to intensified up-front treatment in patients with gastric cancer  and 
other patient groups.  
7.2 PAPER II 
We found no significant change, positive or negative, in the average QoL during the 
treatment period compared to baseline in the GATAC study. There was, however, a trend for 
improved mean and median scores for global health and QoL during the treatment. This is of 
clinical importance as there was no evidence that the cytotoxic treatment had a negative 
impact on patients QoL for the entire patient population. However, patients with no 
radiological response had a decline in the global QoL score. This fact further stresses the 
question of decision making while recommending an appropriate treatment for patients with 
advanced gastric cancer. While making the choice of treatment regimes over time, 
consideration should be made to achieve an optimal response rate or longest possible PFS 
with limited toxicity and sustained QoL. Furthermore, due to the poor prognosis of these 
patients, many will not be candidates for second line treatment at the time of disease 
progression. In this context, our opinion is that further exploration of the prescheduled switch 
of therapy concept is of great interest in this disease. 
7.3 PAPER III 
Despite the inclusion of a CT-based delineation atlas in a clinical protocol, the inter physician 
variations were still large. The resulting clinical dose plans did not, however, show large 
differences in target coverage or doses to OARs. This relationship may perhaps become 
larger and potentially decisive for the clinical outcome, when new planning techniques, i.e. 
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VMAT or PT, are used. Increasing experience in delineation of upper abdominal targets, 
when combined with support by radiologists and well-defined clinical protocols, may 
hopefully lead to higher conformity between physicians in defining treatment targets for RT 
in this region. Our conclusion is that delineation atlases are of crucial importance in 
constructing future clinical study protocols and quality assurance.  
7.4 PAPER IV 
Our data suggest that scanned proton beam therapy in the upper abdomen has a potential for 
sparing of OARs, e.g. preserving kidney function, should be further evaluated in prospective 
controlled trials. The results of our study are comparable to previously reported data in 
comparisons of the doses to the OARs between photons and protons when large PTVs are 
treated in the lower thorax and abdomen. Few trials have reported on the effect of PT on the 
risk of treatment-induced secondary neoplasms when large PTVs are treated. This late side-
effect of RT is, however, of growing significance in the context of increasing cure rates. The 
influence of RT on the risk of secondary tumors, alongside the OARs doses, should be 
considered when choosing the treatment technique. This is of importance foremost in 
individuals with high-risk of developing treatment-induced neoplasms, i.e. pediatric patients 
and young adults, but also for patients large irradiated target volumes. 
7.5 PAPER V 
The uncertainties in dose delivery, due to intestinal gas variations and breathing movement 
resulting in inhomogeneity, have often been used as an argument against the use of protons in 
the irradiation of tumors in the thorax and abdomen. As a result, in treatment planning for 
abdominal targets, the scattered proton technique has been dominating. The scattering 
technique does not, however, have the same magnitude of normal tissue sparing.   
Proton treatment with pencil beam scanning, at this dose level, can be considered feasible 
from the organ sparing point of view. Nevertheless, the effects of the intestinal gas variations 
on the PTV and CTV coverage are large, stressing the necessity for an adaptive approach to 
proton treatment in the upper abdominal region. Today, the image guided (IGRT) based, 
“plan of the day” approach is applied at some proton centers. Other techniques for adaptive 
therapy are developing at a fast pace, i.e. online planning on daily imaging CT scans, 
suggesting that methods of handling these uncertainties can be resolved in the near future. 
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